Patent Grant
10952468
Provided herein is a method of delivering nicotine to a user comprising operating an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure >20 mmHg at 200° C., and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
Provided herein is a method of delivering nicotine to a user comprising operating an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C., and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
Provided herein is a method of delivering nicotine to a user comprising operating an electronic cigarette wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point, and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
Provided herein is a method of delivering nicotine to a user comprising providing an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point, and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
Provided herein is a method of delivering nicotine to the blood of a user, said method comprising providing an aerosol that is inhaled by the user from an electronic cigarette that comprises a nicotine salt formulation wherein providing the aerosol comprises the electronic cigarette heating the formulation thereby generating the aerosol, wherein the aerosol is effective in delivering a level of nicotine in the blood of the user that is at least 5 ng/mL at about 1.5 minutes after a first puff of ten puffs of the aerosol, each puff taken at 30 second intervals.
Provided herein is a nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
Provided herein is a nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
Provided herein is a nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
Provided herein is a nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
Provided herein is a nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
Provided herein is a nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
Provided herein is a nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C., and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
Provided herein is a use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C., and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
Provided herein is a use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point, and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
Provided herein is a use of a nicotine salt formulation for delivery of nicotine to the blood of a user from an electronic cigarette, wherein the nicotine salt formulation in the electronic cigarette is heated to form an aerosol which delivers a level of nicotine in the blood of the user that is at least 5 ng/mL at about 1.5 minutes after a first puff of ten puffs of the aerosol, each puff taken at 30 second intervals.
Provided herein is a use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point, and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
Provided herein is a cartomizer for an electronic cigarette comprising:
Provided herein is a cartomizer for an electronic cigarette comprising:
Provided herein is a cartomizer for an electronic cigarette comprising:
Provided herein is a cartomizer for an electronic cigarette comprising:
Provided herein is an electronic cigarette for generating an inhalable aerosol comprising:
Provided herein is an electronic cigarette for generating an inhalable aerosol comprising:
Provided herein is an electronic cigarette for generating an inhalable aerosol comprising:
Provided herein is an electronic cigarette for generating an inhalable aerosol comprising:
Provided herein is a cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
Provided herein is a cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
Provided herein is a cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
Provided herein is a kit comprising:
Provided herein is a kit comprising:
Provided herein is a kit comprising:
Provided herein is a kit comprising:
All publications, patents and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.
A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are used, and the accompanying drawings of which:
Nicotine is a chemical stimulant and increases heart rate and blood pressure when provided to an individual or animal. Nicotine transfer to an individual is associated with a feeling of physical and/or emotional satisfaction. Conflicting reports have been published regarding the transfer efficiency of free base nicotine in comparison to mono- or di-protonated nicotine salts. Studies on the transfer efficiency of free base nicotine and nicotine salts are complex and have yielded unpredictable results. Further, such transfer efficiency studies have been performed under extremely high temperature conditions, comparable to smoking; therefore, they offer scant guidance on the transfer efficiency of free base nicotine and nicotine salts under low-temperature vaporization conditions. Some reports have posited that nicotine free base should give rise to a greater satisfaction in a user than any corresponding nicotine salt.
It has been unexpectedly discovered herein that certain nicotine salt formulations provide satisfaction in an individual superior to that of free base nicotine, and more comparable to the satisfaction in an individual smoking a traditional cigarette. The satisfaction effect is consistent with an efficient transfer of nicotine to the lungs of an individual and a rapid rise of nicotine absorption in the plasma as shown, for non-limiting example, in Example 8, at least. It has also been unexpectedly discovered herein that certain nicotine salt formulations provide greater satisfaction than other nicotine salt formulations, and such effect has been shown in blood plasma levels of example nicotine salt formulations herein, for non-limiting example, in Example 8, at least. These results show a difference in rate of nicotine uptake in the blood that is higher for some nicotine salt formulations aerosolized by an electronic cigarette than for other nicotine salt formulations, and likewise higher than nicotine freebase formulations, while the peak concentration of the nicotine in the blood and total amount of nicotine delivered appears comparable to a traditional cigarette, and do not appear to vary significantly between the various nicotine formulations. Therefore, described herein are nicotine salt formulations for use in an electronic cigarette, or the like, that provide a general satisfaction effect consistent with an efficient transfer of nicotine to the lungs of an individual and a rapid rise of nicotine absorption in the plasma. Provided herein, therefore, are devices, formulation of nicotine salts, systems, cartomizers, kits and methods that are used to inhale an aerosol generated from a nicotine salt liquid formulation through the mouth or nose as described herein or as would be obvious to one of skill in the art upon reading the disclosure herein.
Consistent with these satisfaction effects, it has unexpectedly been found herein that there is a difference between the Cmax (maximum concentration) and Tmax (time at which the maximum concentration is measured) when measuring blood plasma nicotine levels of freebase nicotine formulations inhaled using a low temperature vaporization device, i.e. electronic cigarette, as compared to the Cmax and Tmax (similarly measuring blood plasma nicotine levels) of a traditional cigarette. Also consistent with these satisfaction effects, it has unexpectedly been found herein that there is a difference between the Cmax (maximum concentration) and Tmax (time at which the maximum concentration is measured) when measuring blood plasma nicotine levels of freebase nicotine formulations inhaled using a low temperature vaporization device, i.e. electronic cigarette, as compared to the Cmax and Tmax (similarly measuring blood plasma nicotine levels) of nicotine salt formulations inhaled using a low temperature vaporization device, i.e. electronic cigarette. Additionally, it has unexpectedly been found that there is a difference between the rate of nicotine uptake in the plasma of users inhaling freebase nicotine formulations using a low temperature vaporization device, i.e. electronic cigarette, as compared to the rate of nicotine uptake in the plasma of users inhaling smoke of a traditional cigarette. Furthermore, it has unexpectedly been found that there is a difference between the rate of nicotine uptake in the plasma of users inhaling freebase nicotine formulations using a low temperature vaporization device, i.e. electronic cigarette, as compared to the rate of nicotine uptake in the plasma of users inhaling nicotine salt formulations using a low temperature vaporization device, i.e. electronic cigarette.
Thus, looking at freebase nicotine as a source of nicotine in compositions used in e-cigarettes, freebase nicotine compositions' delivery of nicotine to blood when inhaled using is not necessarily comparable in blood plasma levels (Cmax and Tmax) to a traditional cigarette's nicotine delivery to blood when inhaled. Freebase nicotine compositions' delivery of nicotine to blood when inhaled using is not necessarily comparable in blood plasma levels (Cmax and Tmax) to nicotine salt formulations' nicotine delivery to blood when inhaled. Freebase nicotine compositions' delivery of nicotine to blood when inhaled using is not necessarily comparable in blood plasma levels when measuring the rate of nicotine uptake in the blood within the first 0-5 minutes to a traditional cigarette's nicotine delivery to blood when inhaled. Freebase nicotine compositions' delivery of nicotine to blood when inhaled using necessarily is not comparable in blood plasma levels when measuring the rate of nicotine uptake in the blood within the first 0-5 minutes to nicotine salt formulations' nicotine delivery to blood when inhaled.
Also consistent with these satisfaction effects, it has unexpectedly been found herein that while there appears to be comparable Cmax and Tmax values (measuring blood plasma nicotine levels) of nicotine salt formulations inhaled using a low temperature vaporization device, i.e. electronic cigarette, as compared to the Cmax and Tmax (similarly measuring blood plasma nicotine levels) of a traditional cigarette, there is a demonstrable difference between the rate of nicotine uptake in the plasma of users inhaling certain nicotine salt formulations using a low temperature vaporization device, i.e. electronic cigarette, as compared to the rate of nicotine uptake in the plasma of users inhaling other nicotine salt formulations using a low temperature vaporization device, i.e. electronic cigarette. It is also unexpected that while the Cmax and Tmax values are comparable to those of a traditional cigarette, (or are approaching that of a traditional cigarette), the rate of nicotine uptake in the plasma of blood of users is higher in certain nicotine salt formulations than that of the traditional cigarette. The nicotine salt formulations which demonstrate the quickest rate of nicotine uptake in the plasma were more preferred in satisfaction evaluations, and were rated more equivalent to cigarette satisfaction than the nicotine salt formulations showing the slowest rates of rise of nicotine in the subjects' blood plasma. In addition, doubling the concentration of the nicotine salt in the formulation may not necessarily impact the rate of absorption of nicotine in the blood (see, for non-limiting example Example 8, nicotine benzoate tested in 4% and 2% concentrations).
Thus, looking at nicotine salt formulations used in e-cigarettes, nicotine salt formulations delivered using an e-cigarette appear comparable in Cmax and Tmax values (measuring blood plasma nicotine levels), however, not all nicotine salts perform similarly to each other or to a traditional cigarette with respect to the rate of nicotine uptake in the blood at early time periods (0-1.5 minutes). These results are unexpected. Nicotine salt formulations made using acids having a Vapor Pressure between 20-300 mmHg @ 200° C., or Vapor Pressure>20 mmHg @ 200° C., or a Vapor Pressure from 20 to 300 mmHg @ 200° C., or a Vapor Pressure from 20 to 200 mmHg @ 200° C., a Vapor Pressure between 20 and 300 mmHg @ 200° C. appear to have a higher rate of nicotine uptake in the blood at early time periods (0-1.5 minutes, 0-3 minutes, 0-2 minutes, 0-4 minutes for non-limiting example) than other nicotine salt formulations, however, they also provide satisfaction comparable to a traditional cigarette or closer to a traditional cigarette (as compared to other nicotine salt formulations or as compared to nicotine freebase formulations). For non-limiting example, acids that meet one or more criteria of the prior sentence include salicylic acid, sorbic acid, benzoic acid, lauric acid, and levulinic acid. Nicotine salt formulations made using acids that have a difference between boiling point and melting point of at least 50° C., and a boiling point greater than 160° C., and a melting point less than 160° C. appear to have a higher rate of nicotine uptake in the blood at early time periods (0-1.5 minutes, 0-3 minutes, 0-2 minutes, 0-4 minutes for non-limiting example) than other nicotine salt formulations, however, they also provide satisfaction comparable to a traditional cigarette or closer to a traditional cigarette (as compared to other nicotine salt formulations or as compared to nicotine freebase formulations). For non-limiting example, acids that meet the criteria of the prior sentence include salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid. Nicotine salt formulations made using acids that have a difference between boiling point and melting point of at least 50° C., and a boiling point at most 40° C. less than operating temperature, and a melting point at least 40° C. lower than operating temperature appear to have a higher rate of nicotine uptake in the blood at early time periods (0-1.5 minutes, 0-3 minutes, 0-2 minutes, 0-4 minutes for non-limiting example) than other nicotine salt formulations, however, they also provide satisfaction comparable to a traditional cigarette or closer to a traditional cigarette (as compared to other nicotine salt formulations or as compared to nicotine freebase formulations). Operating temperature can be 100° C. to 300° C., or about 200° C., about 150° C. to about 250° C., 180° C. to 220° C., about 180° C. to about 220° C., 185° C. to 215° C., about 185° C. to about 215° C., about 190° C. to about 210° C., 190° C. to 210° C., 195° C. to 205° C., or about 195° C. to about 205° C. For non-limiting example, acids that meet the criteria of the prior sentence include salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid. Combinations of these criteria for preference of certain nicotine salt formulations are contemplated herein.
Other reasons for excluding certain acids from formulations may be unrelated to the rate of nicotine uptake, however. For example, an acid may be inappropriate for use with the device materials (corrosive or otherwise incompatible). Sulfuric acid is an example of this, which may be inappropriate for the e-cigarette device. An acid may be inappropriate for use in inhalation or for toxicity reasons—thus not be compatible for human consumption, ingestion, or inhalation. Sulfuric acid again is an example of this, which may be inappropriate for a user of an e-cigarette device, depending on the embodiment of the composition. An acid that is bitter or otherwise bad-tasting may also provide a reason for exclusion, such as acetic acid in some embodiments. Acids that oxidize at room temperature or at operating temperature may be inappropriate for certain embodiments, for example, sorbic acid, as this indicates a decomposition or reaction or instability that may be undesirable in the formulation. Decomposition of acids at room or operating temperatures may also indicate that the acid is inappropriate for use in the embodiment formulations. For example, citric acid decomposes at 175° C., and malic acid decomposes at 140° C., thus for a device operating at 200° C., these acids may not be appropriate. Acids that have poor solubility in the composition constituents may be inappropriate for use in certain embodiments of the compositions herein. For example, nicotine bitartrate with a composition of nicotine and tartaric acid as 1:2 molar ratio will not produce a solution at a concentration of 0.5% (w/w) nicotine or higher and 0.9% (w/w) tartaric acid or higher in propylene glycol (PG) or vegetable glycerin (VG) or any mixture of PG and VG at ambient conditions. As used herein, weight percentage (w/w) refers to the weight of the individual component over the weight of the total formulation.
As used in this specification and the claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
The term “organic acid” as used herein, refers to an organic compound with acidic properties (e.g., by Broøsted-Lowry definition, or Lewis definition). A common organic acid is the carboxylic acids, whose acidity is associated with their carboxyl group —COOH. A dicarboxylic acid possesses two carboxylic acid groups. The relative acidity of an organic is measured by its pKa value and one of skill in the art knows how to determine the acidity of an organic acid based on its given pKa value. The term “keto acid” as used herein, refers to organic compounds that contain a carboxylic acid group and a ketone group. Common types of keto acids include alpha-keto acids, or 2-oxoacids, such as pyruvic acid or oxaloacetic acid, having the keto group adjacent to the carboxylic acid; beta-keto acids, or 3-oxoacids, such as acetoacetic acid, having the ketone group at the second carbon from the carboxylic acid; gamma-keto acids, or 4-oxoacids, such as levulinic acid, having the ketone group at the third carbon from the carboxylic acid.
The term “electronic cigarette” or “e-cigarette” or “low temperature vaporization device” as used herein, refers to an electronic inhaler that vaporizes a liquid solution into an aerosol mist, simulating the act of tobacco smoking. The liquid solution comprises a formulation comprising nicotine. There are many electronic cigarettes which do not resemble conventional cigarettes at all. The amount of nicotine contained can be chosen by the user via the inhalation. In general, an electronic cigarette contains three essential components: a plastic cartridge that serves as a mouthpiece and a reservoir for liquid, an “atomizer” that vaporizes the liquid, and a battery. Other embodiment electronic cigarettes include a combined atomizer and reservoir, called a “cartomizer” that may or may not be disposable, a mouthpiece that may be integrated with the cartomizer or not, and a battery.
As used in this specification and the claims, unless otherwise stated, the term “about” refers to variations of 1%, 2%, 3%, 4%, 5%, 10%, 15%, or 25%, depending on the embodiment.
Suitable carriers (e.g., a liquid solvent) for the nicotine salts described herein include a medium in which a nicotine salt is soluble at ambient conditions, such that the nicotine salt does not form a solid precipitate. Examples include, but are not limited to, glycerol, propylene glycol, trimethylene glycol, water, ethanol and the like, as well as combinations thereof. In some embodiments, the liquid carrier comprises 0% to 100% of propylene glycol and 100% to 0% of vegetable glycerin. In some embodiments, the liquid carrier comprises 10% to 70% of propylene glycol and 90% to 30% of vegetable glycerin. In some embodiments, the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin. In some embodiments, the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
The formulations described herein vary in concentration. In some formulations, a dilute concentration of the nicotine salt in the carrier is utilized. In some formulations, a less dilute concentration of the nicotine salt in the carrier is utilized. In some formulations the concentration of nicotine in the nicotine salt formulation is about 1% (w/w) to about 25% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is about 1% (w/w) to about 20% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is about 1% (w/w) to about 18% (w/w). In some embodiments the concentration of nicotine in the nicotine salt formulation is about 1% (w/w) to about 15% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is about 4% (w/w) to about 12% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is about 4% (w/w). In some embodiments the concentration of nicotine in the nicotine salt formulation is about 2% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 1% (w/w) to 25% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 1% (w/w) to 20% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 1% (w/w) to 18% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 1% (w/w) to 15% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 4% (w/w) to 12% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 4% (w/w). In some formulations the concentration of nicotine in the nicotine salt formulation is 2% (w/w). In some formulations, a less dilute concentration of one nicotine salt is used in conjunction with a more dilute concentration of a second nicotine salt. In some formulations, the concentration of nicotine in the first nicotine salt formulation is about 1% to about 20%, and is combined with a second nicotine salt formulation having a concentration of nicotine therein from about 1% to about 20% or any range or concentration therein. In some formulations, the concentration of nicotine in the first nicotine salt formulation is 1% to 20%, and is combined with a second nicotine salt formulation having a concentration of nicotine therein from 1% to 20% or any range or concentration therein. As used with respect to concentrations of nicotine in the nicotine salt formulations, the term “about” refers to ranges of 0.05% (i.e. if the concentration is about 2%, the range is 1.95%-2.05%), 0.1 (i.e. if the concentration is about 2%, the range is 1.9%-2.1%), 0.25 (i.e. if the concentration is about 2%, the range is 1.75%-2.25%), 0.5 (i.e. if the concentration is about 2%, the range is 1.5%-2.5%), or 1 (i.e. if the concentration is about 4%, the range is 3%-5%), depending on the embodiment.
Nicotine salts are formed by the addition of a suitable acid, including organic or inorganic acids. In some formulations provided herein, suitable organic acids are carboxylic acids. Examples of organic carboxylic acids disclosed herein are monocarboxylic acids, dicarboxylic acids (organic acid containing two carboxylic acid groups), carboxylic acids containing an aromatic group such as benzoic acids, hydroxycarboxylic acids, heterocyclic carboxylic acids, terpenoid acids, sugar acids; such as the pectic acids, amino acids, cycloaliphatic acids, aliphatic carboxylic acids, keto carboxylic acids, and the like. In some formulations provided herein, the organic acids used herein are monocarboxylic acids. Nicotine salts are formed from the addition of a suitable acid to nicotine. In some formulations provided herein, the stoichiometric ratios of the nicotine to acid (nicotine:acid) are 1:1, 1:2, 1:3, 1:4, 2:3, 2:5, 2:7, 3:4, 3:5, 3:7, 3:8, 3:10, 3:11, 4:5, 4:7, 4:9, 4:10, 4:11, 4:13, 4:14, 4:15, 5:6, 5:7, 5:8, 5:9, 5:11, 5:12, 5:13, 5:14, 5:16, 5:17, 5:18, or 5:19. In some formulations provided herein, the stoichiometric ratios of the nicotine to acid are 1:1, 1:2, 1:3, or 1:4 (nicotine:acid).
Nicotine is an alkaloid molecule that comprises two basic nitrogens. It may occur in different states of protonation. For example, if no protonation exists, nicotine is referred to as the “free base.” If one nitrogen is protonated, then the nicotine would be “mono-protonated.”
Nicotine salt formulations may be formed by adding a suitable acid to nicotine, stirring the neat mixture at ambient temperature or at elevated temperature, and then diluting the neat mixture with a carrier mixture, such as a mixture of propylene glycol and glycerin. In some embodiments, the suitable acid is completely dissolved by the nicotine prior to dilution. The suitable acid may not completely dissolved by the nicotine prior to dilution. The addition of the suitable acid to the nicotine to form a neat mixture may cause an exothermic reaction. The addition of the suitable acid to the nicotine to form a neat mixture may be conducted at 55° C. The addition of the suitable acid to the nicotine to form a neat mixture may be conducted at 90° C. The neat mixture may be cooled to ambient temperature prior to dilution. The dilution may be carried out at elevated temperature.
Nicotine salt formulations may be prepared by combining nicotine and a suitable acid in a carrier mixture, such as a mixture of propylene glycol and glycerin. The mixture of nicotine and a first carrier mixture is combined with a mixture of a suitable acid in a second carrier mixture. In some embodiments, the first and second carrier mixtures are identical in composition. In some embodiments, the first and second carrier mixtures are not identical in composition. In some embodiments, heating of nicotine/acid/carrier mixture is required to facilitate complete dissolution.
In some embodiments, nicotine salt formulations may be prepared and added to a solution of 3:7 ratio by weight of propylene glycol (PG)/vegetable glycerin (VG), and mixed thoroughly. While described herein as producing 10 g of each of the formulations, all procedures noted infra are scalable. Other manners of formulation may also be employed form the formulations noted infra, without departing from the disclosure herein, and as would be known to one of skill in the art upon reading the disclosure herein.
The optimal nicotine salt formulation may be determined by the vapor pressure of the constituent acid. In some embodiments, the nicotine salt formulations comprise an acid with a vapor pressure that is similar to the vapor pressure of free base nicotine. In some embodiments, the nicotine salt formulations are formed from an acid with a vapor pressure that is similar to the vapor pressure of free base nicotine at the heating temperature of the device.
The nicotine salt liquid formulation for generating an inhalable aerosol upon heating in an electronic cigarette may comprise a nicotine salt in a biologically acceptable liquid carrier; wherein the acid used to form said nicotine salt is characterized by a vapor pressure between 20-4000 mmHg at 200° C. In some embodiments, the acid used to form the nicotine salt is characterized by vapor pressure between 20-2000 mmHg at 200° C. In some embodiments, the acid used to form the nicotine salt is characterized by vapor pressure between 100-300 mmHg at 200° C.
Unexpectedly, different nicotine salt formulations produced varying degrees of satisfaction in an individual. In some embodiments, the extent of protonation of the nicotine salt affected satisfaction, such that more protonation was less satisfying as compared to less protonation. The nicotine salt formed may be monoprotonated. The nicotine salt formed may be diprotonated. The nicotine salt may exist in more than one protonation state, e.g., an equilibrium of mono-protonated and di-protonated nicotine salts. The extent of protonation of the nicotine molecule may be dependent upon the stoichiometric ratio of nicotine:acid used in the salt formation reaction. The extent of protonation of the nicotine molecule may be dependent upon the solvent. The extent of protonation of the nicotine molecule may be unknown. In some embodiments, monoprotonated nicotine salts produced a high degree of satisfaction in the user. For example, nicotine benzoate and nicotine salicylate are mono-protonated nicotine salts and all produce a high degree of satisfaction in the user. The reason for this trend may be explained by a mechanism of action wherein the nicotine is first deprotonated prior to transfer to the vapor with the constituent acid and then retained and stabilized after re-protonated by the acid going down stream to the lungs of the user. It may be easier to remove one proton versus two protons, thus resulting in better transfer efficiency. In addition, the lack of satisfaction of free base nicotine indicates that a second factor may be important. A nicotine salt may be best performing when it is at its optimal extent of protonation, depending on the salt. For example, nicotine pyruvate is a nicotine salt with 1:2 nicotine:acid ratio. The formulation containing nicotine pyruvate (1:2) may deliver more satisfaction to the user than the one containing same amount of nicotine but only half amount of pyruvic acid, i.e. nicotine pyruvate (1:1). This may be explained as 1 mole of nicotine produces a salt with 2 moles of pyruvic acid. When there is not enough pyruvic acid to associate with all nicotine molecules, the free base nicotine left unprotonated in the formulation may reduce the satisfaction the formulation provides.
The flavor of the constituent acid used in the salt formation may be a consideration in choosing the acid. A suitable acid may have minimal or no toxicity to humans in the concentrations used. A suitable acid may be compatible with the electronic cigarette components it contacts or could contact at the concentrations used. That is, such acid does not degrade or otherwise react with the electronic cigarette components it contacts or could contact. The odor of the constituent acid used in the salt formation may be a consideration in choosing a suitable acid. The concentration of the nicotine salt in the carrier may affect the satisfaction in the individual user. In some embodiments, the flavor of the formulation is adjusted by changing the acid. In some embodiments, the flavor of the formulation is adjusted by adding exogenous flavorants. In some embodiments, an unpleasant tasting or smelling acid is used in minimal quantities to mitigate such characteristics. In some embodiments, exogenous pleasant smelling or tasting acid is added to the formulation. Examples of salts which can provide flavor and aroma to the mainstream aerosol at certain levels include nicotine acetate, nicotine oxalate, nicotine malate, nicotine isovalerate, nicotine lactate, nicotine citrate, nicotine phenylacetate and nicotine myristate.
Nicotine salt formulations may generate an inhalable aerosol upon heating in an electronic cigarette. The amount of nicotine or nicotine salt aerosol inhaled may be user-determined. The user may, for example, modify the amount of nicotine or nicotine salt inhaled by adjusting his inhalation strength.
Formulations are described herein comprising two or more nicotine salts. In some embodiments, wherein a formulation comprises two or more nicotine salts, each individual nicotine salt is formed as described herein.
Nicotine salt formulations, as used herein, refer to a single or mixture of nicotine salts with other suitable chemical components used for e-cigarette, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. In certain embodiments, the nicotine salt formulation is stirred at ambient conditions for 20 minutes. In certain embodiments, the nicotine salt formulation is heated and stirred at 55 C for 20 minutes. In certain embodiments, the nicotine salt formulation is heated and stirred at 90 C for 60 minutes. In certain embodiments, the formulation facilitates administration of nicotine to an organism (e.g., lung).
The nicotine of nicotine salt formulations provided herein is either naturally occurring nicotine (e.g., from extract of nicotineous species such as tobacco), or synthetic nicotine. In some embodiments, the nicotine is (−)-nicotine, (+)-nicotine, or a mixture thereof. In some embodiments, the nicotine is employed in relatively pure form (e.g., greater than about 80% pure, 85% pure, 90% pure, 95% pure, or 99% pure). In some embodiments, the nicotine for nicotine salt formulation provided herein is “water clear” in appearance in order to avoid or minimize the formation of tarry residues during the subsequent salt formation steps.
Nicotine salt formulations used for e-cigarettes described herein, in some embodiments, have a nicotine concentration of about 0.5% (w/w) to about 20% (w/w), wherein the concentration is of nicotine weight to total solution weight, i.e. (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 20% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 18% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 15% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 4% (w/w) to about 12% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 18% (w/w), about 3% (w/w) to about 15% (w/w), or about 4% (w/w) to about 12% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 0.5% (w/w) to about 10% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 0.5% (w/w) to about 5% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 0.5% (w/w) to about 4% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 0.5% (w/w) to about 3% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 0.5% (w/w) to about 2% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 0.5% (w/w) to about 1% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 10% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 5% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 4% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 3% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 1% (w/w) to about 2% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 2% (w/w) to about 10% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 2% (w/w) to about 5% (w/w). In certain embodiments, nicotine salt formulations provided herein have a nicotine concentration of about 2% (w/w) to about 4% (w/w). Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% (w/w), or more, including any increments therein. Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 5% (w/w). Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 4% (w/w). Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 3% (w/w). Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 2% (w/w). Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 1% (w/w). Certain embodiments provide a nicotine salt formulation having a nicotine concentration of about 0.5% (w/w).
The formulation further may comprise one or more flavorants.
The suitable acid for the nicotine salt formulation may have a vapor pressure>20 mmHg at 200° C. and is non-corrosive to the electronic cigarette or is non-toxic to humans. In some embodiments, the suitable acid for nicotine salt formation is selected from the group consisting of salicylic acid, formic acid, sorbic acid, acetic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
The suitable acid for the nicotine salt formulation may have a vapor pressure of about 20 to 200 mmHg at 200° C. and is non-corrosive to the electronic cigarette or is non-toxic to humans. In some embodiments, the suitable acid for nicotine salt formation is selected from the group consisting of salicylic acid, benzoic acid, lauric acid, and levulinic acid.
The suitable acid for the nicotine salt formulation may have a melting point<160° C., a boiling point>160° C., at least a 50-degree difference between the melting point and the boiling point, and is non-corrosive to the electronic cigarette or is non-toxic to humans. In some embodiments, the suitable acid for nicotine salt formation has a melting point at least 40 degrees lower than the operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, at least a 50-degree difference between the melting point and the boiling point, and is non-corrosive to the electronic cigarette or is non-toxic to humans; wherein the operating temperature is 200° C. In some embodiments, the suitable acid for nicotine salt formation is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
The suitable acid for the nicotine salt formulation does not decompose at the operating temperature of the electronic cigarette. In some embodiments, the suitable acid for nicotine salt formation does not oxidize at the operating temperature of the electronic cigarette. In some embodiments, the suitable acid for nicotine salt formation does not oxidize at room temperature. In some embodiments, the suitable acid for nicotine salt formation does not provide an unpleasant taste. In some embodiments, the suitable acid for nicotine salt formation has good solubility in a liquid formulation for use in an electronic cigarette.
Provided herein is an electronic cigarette 2 having a fluid storage compartment 4 comprising an embodiment nicotine salt formulation of any embodiment described herein within the fluid storage compartment described herein. An embodiment is shown in
Provided herein is a cartomizer 18 for an electronic cigarette 2 having a fluid storage compartment 4 comprising an embodiment nicotine salt formulation of any embodiment described herein within the fluid storage compartment described herein. The cartomizer 18 embodiment of
Various nicotine formulations were prepared and added to a solution of 3:7 ratio by weight of propylene glycol (PG)/vegetable glycerin (VG), and mixed thoroughly. The examples shown below were used to make 10 g of each of the formulations. All procedures are scalable.
For example, in order to make nicotine formulations with a final nicotine free base equivalent concentration of 2% (w/w), the following procedures were applied to each individual formulation.
For example, in order to make nicotine salt formulations with a final nicotine free base equivalent concentration of 3% (w/w), the following procedures were applied to each individual formulation.
For example, in order to make nicotine salt formulations with a final nicotine free base equivalent concentration of 4% (w/w), the following procedures were applied to each individual formulation.
Various formulations comprising different nicotine salts can be prepared similarly, or different concentrations of the above-noted nicotine formulations or other nicotine salt formulations can be prepared as one of skill in the art would know to do upon reading the disclosure herein.
Various formulations comprising two or more nicotine salts can be prepared similarly in a solution of 3:7 ratio of propylene glycol (PG)/vegetable glycerin (VG). For example, 0.43 g (2.5% w/w nicotine) of nicotine levulinate salt and 0.34 g (2.5% w/w nicotine) of nicotine acetate salt are added to 9.23 g of PG/VG solution, to achieve a 5% w/w nicotine formulation.
Also provided is another exemplary formulation. For example, 0.23 g (1.33% w/w nicotine) of nicotine benzoate salt (molar ratio 1:1 nicotine/benzoic acid), 0.25 g (1.33% w/w nicotine) of nicotine salicylate salt (molar ratio 1:1 nicotine/salicylic acid) and 0.28 g (1.34% w/w nicotine) of nicotine pyruvate salt (molar ratio 1:2 nicotine/pyruvic acid) are added to 9.25 g of PG/VG solution, to achieve a 5% w/w nicotine formulation.
Exemplary formulations of nicotine levulinate, nicotine benzoate, nicotine succinate, nicotine salicylate, nicotine malate, nicotine pyruvate, nicotine citrate, nicotine freebase, and a control of propylene glycol were prepared as noted in Example 1 in 3% w/w solutions and were administered in the same fashion by an electronic cigarette to the same human subject. About 0.5 mL of each solution was loaded into an “eRoll” cartridge atomizer (joyetech.com) to be used in the study. The atomizer was then attached to an “eRoll” e-cigarette (same manufacturer). The operating temperature was from about 150° C. to about 250° C., or from about 180° C. to about 220° C.
Heart rate measurements were taken for 6 minutes; from 1 minute before start of puffing, for 3 minutes during puffing, and continuing until 2 minutes after end of puffing. The test participant took 10 puffs over 3 minutes in each case. The base heart rate was the average heart rate over the first 1 minute before start of puffing. Heart rate after puffing started was averaged over 20-second intervals. Puffing (inhalation) occurred every 20 seconds for a total of 3 minutes. Normalized heart rate was defined as the ratio between individual heart rate data point and the base heart rate. Final results were presented as normalized heart rate, shown for the first 4 minutes in
In addition to the heart rate study shown in Example 2, nicotine formulations (using 3% w/w nicotine formulations as described in Example 1) were used to conduct a satisfaction study in a single test participant. The test participant, an e-cigarette and/or traditional cigarette user, was required to have no nicotine intake for at least 12 hours before the test. The participant took 10 puffs using an e-cigarette (same as used in Example 2) over 3 minutes in each case, and then was asked to rate the level of physical and emotional satisfaction he or she felt on a scale of 0-10, with 0 being no physical or emotional satisfaction. The results indicated that the least satisfying compound was the nicotine free base. Nicotine benzoate, nicotine salicylate, and nicotine succinate all performed well, followed by nicotine pyruvate, nicotine citrate, and nicotine pyruvate.
Based on the Satisfaction Study, the nicotine salts formulations with acids having vapor pressure ranges between >20 mmHg @ 200° C., or 20-200 mmHg @ 200° C., or 100-300 mmHg @ 200° C. provide more satisfaction than the rest (except the pyruvic acid which has boiling point of 165° C.). For reference, it has been determined that salicylic acid has a vapor pressure of about 135.7 mmHg @ 200° C., benzoic acid has a vapor pressure of about 171.7 mmHg @ 200° C., lauric acid has a vapor pressure of about 38 mmHg @ 200° C., and levulinic acid has a vapor pressure of about 149 mmHg @ 200° C.
A solution of nicotine levulinate in glycerol comprising nicotine salt used: 1.26 g (12.6% w/w) of 1:3 nicotine levulinate 8.74 g (87.4% w/w) of glycerol—Total weight 10.0 g.
Neat nicotine levulinate was added to the glycerol, and mixed thoroughly. L-Nicotine has a molar mass of 162.2 g, and levulinic acid molar mass is 116.1 g. In a 1:3 molar ratio, the percentage of nicotine in nicotine levulinate by weight is given by: 162.2 g/(162.2 g+(3×116.1 g))=31.8% (w/w).
A solution of free base nicotine in glycerol comprising 0.40 g (4.00% w/w) of L-nicotine was dissolved in 9.60 g (96.0% w/w) of glycerol and mixed thoroughly.
Both formulations (TF1 and TF2) were administered in the same fashion by an electronic cigarette to the same human subject: about 0.6 mL of each solution was loaded into “eGo-C” cartridge atomizer (joyetech.com). The atomizer was then attached to an “eVic” e-cigarette (same manufacturer). This model of e-cigarette allows for adjustable voltage, and therefore wattage, through the atomizer. The operating temperature of the e-cigarette is from about 150° C. to about 250° C., or from about 180° C. to about 220° C.
The atomizer in both cases has resistance 2.4 ohms, and the e-cigarette was set to 4.24V, resulting in 7.49 W of power. (P=V{circumflex over ( )}2/R)
Heart rate was measured in a 30-second interval for ten minutes from start of puffing. Test participants took 10 puffs over 3 minutes in each case (solid line (2nd highest peak): cigarette, dark dotted line (highest peak): test formulation 1 (TF1—nicotine salt formulation), light dotted line: test formulation 2 (TF2—nicotine formulation). Comparison between cigarette, TF1, and TF2 is shown in
It is clearly shown in
In addition, the data appears to correlate well with the previous findings shown in
As previously noted in the Satisfaction Study, the nicotine salts formulations with acids having vapor pressures between 20-300 mmHg @ 200° C. provide more satisfaction than the rest, with the exception of the nicotine salt formulation made with pyruvic acid, which has a boiling point of 165° C., as noted in
Tmax—Time to maximum blood concentration: Based on the results established herein, a user of an e-cigarette comprising the nicotine salt formulation will experience a comparable rate of physical and emotional satisfaction from using a formulation comprising a mixture of nicotine salts prepared with an appropriate acid at least 1.2× to 3× faster than using a formulation comprising a freebase nicotine. As illustrated in
Again this would not be inconsistent with the data from
Further, when considering peak satisfaction levels (achieved at approximately 120 seconds from the initiation of puffing (time=0) and looking at the slope of the line for a normalized heart rate, the approximate slope of those nicotine salt formulations that exceeded the freebase nicotine formulation range between 0.0054 hrn/sec and 0.0025 hrn/sec. By comparison, the slope of the line for the freebase nicotine formulation is about 0.002. This would suggest that the concentration of available nicotine will be delivered to the user at a rate that is between 1.25 and 2.7 times faster than a freebase formulation.
In another measure of performance; Cmax—Maximum blood nicotine concentration; it is anticipated that similar rates of increase will be measured in blood nicotine concentration, as those illustrated above. That is, it was anticipated based on the findings herein, and unexpected based on the art known to date, that there would be comparable Cmax between the common cigarette and certain nicotine salt formulations, but with a lower Cmax in a freebase nicotine solution.
Similarly, anticipated based on the findings herein, and unexpected based on the art known to date, that certain nicotine salt formulations would have higher rate of nicotine uptake levels in the blood at early time periods. Indeed, Example 8 presents data for multiple salt formulations consistent with these predictions which were made based on the findings and tests noted herein, and unexpected compared to the art available to date.
Exemplary formulations of nicotine levulinate, nicotine benzoate, nicotine succinate, nicotine salicylate, nicotine malate, nicotine pyruvate, nicotine citrate, nicotine sorbate, nicotine laurate, nicotine freebase, and a control of propylene glycol are prepared as noted in Example 1 and are administered in the same fashion by an electronic cigarette to the same human subject. About 0.5 mL of each solution is loaded into an “eRoll” cartridge atomizer (joyetech.com) to be used in the study. The atomizer is then attached to an “eRoll” e-cigarette (same manufacturer). The operating temperature of the e-cigarette is from about 150° C. to about 250° C., or from about 180° C. to about 220° C.
Heart rate measurements are taken for 6 minutes; from 1 minute before start of puffing, for 3 minutes during puffing, and continuing until 2 minutes after end of puffing. The test participant takes 10 puffs over 3 minutes in each case. The base heart rate is the average heart rate over the first 1 minute before start of puffing. Heart rate after puffing started is averaged over 20-second intervals. Normalized heart rate is defined as the ratio between individual heart rate data point and the base heart rate. Final results are presented as normalized heart rate.
Blood plasma testing was conducted on three subjects (n=3). Eight test articles were used in this study: one reference cigarette and seven blends used in an e-cigarette device having an operating temperature of the e-cigarette from about 150° C. to about 250° C., or from about 180° C. to about 220° C. The reference cigarette was Pall Mall (New Zealand). Seven blends were tested in the e-cigarette: 2% free base, 2% benzoate, 4% benzoate, 2% citrate, 2% malate, 2% salicylate, and 2% succinate. Except for 2% succinate (n=1), all other blends have n=3. The seven blends were liquid formulations prepared as described in Example 1.
The concentration of nicotine in each of the formulations was confirmed using UV spectrophotometer (Cary 60, manufactured by Agilent). The sample solutions for UV analysis were made by dissolving 20 mg of each of the formulations in 20 mL 0.3% HCl in water. The sample solutions were then scanned in UV spectrophotometer and the characteristic nicotine peak at 259 nm was used to quantify nicotine in the sample against a standard solution of 19.8 □g/mL nicotine in the same diluent. The standard solution was prepared by first dissolving 19.8 mg nicotine in 10 mL 0.3% HCl in water followed by a 1:100 dilution with 0.3% HCl in water. Nicotine concentrations reported for all formulations were within the range of 95%-105% of the claimed concentrations
All subjects were able to consume 30-55 mg of the liquid formulation of each tested blend using the e-cigarette.
Literature results: C. Bullen et al, Tobacco Control 2010, 19:98-103
Cigarette (5 min adlib, n=9): Tmax=14.3 (8.8-19.9), Cmax=13.4 (6.5-20.3)
1.4% E-cig (5 min adlib, n=8): Tmax=19.6 (4.9-34.2), Cmax=1.3 (0.0-2.6)
Nicorette Inhalator (20 mg/20 min, n=10): Tmax=32.0 (18.7-45.3), Cmax=2.1 (1.0-3.1)
Estimated Cmax of 2% nicotine blends:
Cmax=Mass consumed*Strength*Bioavailability/(Vol of Distribution*Body Weight)=40 mg*2%*80%/(2.6 L/kg*75 kg)=3.3 ng/mL
Estimated Cmax of 4% nicotine blends:
Cmax=Mass consumed*Strength*Bioavailability/(Vol of Distribution*Body Weight)=40 mg*4%*80%/(2.6 L/kg*75 kg)=6.6 ng/mL
Pharmacokinetic profiles of the blood plasma testing are shown in
Comparison of Tmax and Cmax of the seven blends and reference cigarette are shown in
Rates of nicotine uptake in the blood of the users of each sample within the first 90 seconds are shown in Table 3.
Although the Tmax and Cmax values are comparable between the tested blends and the reference cigarette (with the exception of the 2% free base blend), the rates of nicotine absorption within the first 90 seconds differed among the test articles. In particular, four blends (2% salicylate, 2% benzoate, 4% benzoate, and 2% citrate) showed markedly higher rates of absorption within the first 90 seconds compared to the other blends and with the reference cigarette. These four blends contain salts (salicylate, benzoate, and citrate) which performed well in the Satisfaction Study of Example 3. Moreover, 2% benzoate and 4% benzoate had comparable rates of absorption, suggesting that a lower concentration of nicotinic salt may not adversely impact the rate of absorption.
Blood plasma testing is conducted on 24 subjects (n=24). Eight test articles are used in this study: one reference cigarette and seven blends delivered to a user in an e-cigarette as an aerosol. The operating temperature of the e-cigarette is from about 150° C. to about 250° C., or from about 180° C. to about 220° C. The reference cigarette is Pall Mall (New Zealand). Seven blends are tested: 2% free base, 2% benzoate, 4% benzoate, 2% citrate, 2% malate, 2% salicylate, and 2% succinate. The seven blends are liquid formulations prepared according to protocols similar to that described infra and in Example 1.
All subjects are to consume 30-55 mg of the liquid formulation of each tested blend. Ten puffs are to be taken at 30 sec intervals starting at time=0 and continuing for 4.5 minutes. Blood plasma testing is to occur for at least 60 minutes from the first puff (t=0) Pharmacokinetic data (e.g., Cmax, Tmax, AUC) for nicotine in the plasma of users are obtained at various time periods during those 60 minutes, along with rates of nicotine absorption within the first 90 seconds for each test article.
Blood plasma testing is conducted on twenty-four subjects (n=24). Eleven test articles are used in this study: one reference cigarette and ten blends delivered to a user in an e-cigarette as an aerosol. The reference cigarette is Pall Mall (New Zealand). The operating temperature of the e-cigarette is from about 150° C. to about 250° C., or from about 180° C. to about 220° C. Ten blends are tested: 2% free base, 2% benzoate, 2% sorbate, 2% pyruvate, 2% laurate, 2% levulinate, 2% citrate, 2% malate, 2% salicylate, and 2% succinate. The ten blends are liquid formulations prepared according to protocols similar to that described infra and in Example 1.
All subjects are to consume 30-55 mg of the liquid formulation of each tested blend. Ten puffs are to be taken at 30 sec intervals starting at time=0 and continuing for 4.5 minutes. Blood plasma testing is to occur for at least 60 minutes from the first puff (t=0). Pharmacokinetic data (e.g., Cmax, Tmax, AUC) for nicotine in the plasma of users are obtained at various time periods during those 60 minutes, along with rates of nicotine absorption within the first 90 seconds for each test article.
Blood plasma testing is conducted on twenty-four subjects (n=24). Twenty-one test articles are used in this study: one reference cigarette and twenty blends delivered to a user in an e-cigarette as an aerosol. The reference cigarette is Pall Mall (New Zealand). The operating temperature of the e-cigarette is from about 150° C. to about 250° C., or from about 180° C. to about 220° C. Twenty blends are tested: 2% free base, 4% free base, 2% benzoate, 4% benzoate, 2% sorbate, 4% sorbate, 2% pyruvate, 4% pyruvate, 2% laurate, 4% laurate, 2% levulinate, 4% levulinate, 2% citrate, 4% citrate, 2% malate, 4% malate, 2% salicylate, 4% salicylate, 2% succinate, and 4% succinate. The twenty blends are liquid formulations prepared according to protocols similar to that described infra and in Example 1.
All subjects are to consume 30-55 mg of the liquid formulation of each tested blend. Ten puffs are to be taken at 30 sec intervals starting at time=0 and continuing for 4.5 minutes. Blood plasma testing is to occur for at least 60 minutes from the first puff (t=0). Pharmacokinetic data (e.g., Cmax, Tmax, AUC) for nicotine in the plasma of users are obtained at various time periods during those 60 minutes, along with rates of nicotine absorption within the first 90 seconds for each test article.
Blood plasma testing is conducted on twenty-four subjects (n=24). Twenty-one test articles are used in this study: one reference cigarette and twenty blends delivered to a user in an e-cigarette as an aerosol. The reference cigarette is Pall Mall (New Zealand). The operating temperature of the e-cigarette is from about 150° C. to about 250° C., or from about 180° C. to about 220° C. Twenty blends are tested: 2% free base, 1% free base, 2% benzoate, 1% benzoate, 2% sorbate, 1% sorbate, 2% pyruvate, 1% pyruvate, 2% laurate, 1% laurate, 2% levulinate, 1% levulinate, 2% citrate, 1% citrate, 2% malate, 1% malate, 2% salicylate, 1% salicylate, 2% succinate, and 1% succinate. The twenty blends are liquid formulations prepared according to protocols similar to that described infra and in Example 1.
All subjects are to consume 30-55 mg of the liquid formulation of each tested blend. Ten puffs are to be taken at 30 sec intervals starting at time=0 and continuing for 4.5 minutes. Blood plasma testing is to occur for at least 60 minutes from the first puff (t=0). Pharmacokinetic data (e.g., Cmax, Tmax, AUC) for nicotine in the plasma of users are obtained at various time periods during those 60 minutes, along with rates of nicotine absorption within the first 90 seconds for each test article.
Further understanding may be gained through contemplation of the numbered embodiments below.
1. A method of delivering nicotine to a user comprising operating an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C., and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
2. A method of delivering nicotine to a user comprising operating an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C., and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
3. A method of delivering nicotine to a user comprising operating an electronic cigarette wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point, and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
4. A method of delivering nicotine to a user comprising providing an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point, and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.
5. The method of any one of embodiments 1-3, wherein an operating temperature is from 150° C. to 250° C.
6. The method of any one of embodiments 1-3, wherein an operating temperature is from 180° C. to 220° C.
7. The method any one of embodiments 1-3, wherein an operating temperature is about 200° C.
8. The method of embodiment 4, wherein the operating temperature is from 150° C. to 250° C.
9. The method of embodiment 4, wherein the operating temperature is from 180° C. to 220° C.
10. The method of embodiment 4, wherein the operating temperature is about 200° C.
11. The method any one of embodiments 1-10, wherein the aerosol comprises condensate of the nicotine salt.
12. The method any one of embodiments 1-10, wherein the aerosol comprises condensate of freebase nicotine.
13. The method any one of embodiments 1-10, wherein the aerosol comprises condensate of freebase nicotine and condensate of the carrier.
14. The method any one of embodiments 1-10, wherein the aerosol comprises condensate of freebase nicotine and condensate of the acid.
15. The method any one of embodiments 1-14, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 5 microns.
16. The method any one of embodiments 1-14, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 1 or 2 microns.
17. The method any one of embodiments 1-14, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 0.7 microns.
18. The method any one of embodiments 1-14, wherein the aerosol comprises condensate in particle sizes from about 0.3 microns to about 0.4 microns.
19. The method any one of embodiments 1-18, wherein the acid is a carboxylic acid.
20. The method of any one of embodiments 1-18, wherein the acid used to form said nicotine salt is an organic acid.
21. The method of embodiment 20, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
22. The method of embodiment 20, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
23. The method of any one of embodiments 1-18, wherein the acid used to form the nicotine salt is salicylic acid.
24. The method of any one of embodiments 1-18, wherein the acid used to form the nicotine salt is benzoic acid.
25. The method of any one of embodiments 1-18, wherein the acid used to form the nicotine salt is pyruvic acid.
26. The method of any one of embodiments 1-18, wherein the acid used to form the nicotine salt is sorbic acid.
27. The method of any one of embodiments 1-18, wherein the acid used to form the nicotine salt is lauric acid.
28. The method of any one of embodiments 1-18, wherein the acid used to form the nicotine salt is levulinic acid.
29. The method of any one of embodiments 1-18, wherein said nicotine salt comprises nicotine pyruvate.
30. The method of any one of embodiments 1-18, wherein said nicotine salt comprises nicotine salicylate.
31. The method of any one of embodiments 1-18, wherein said nicotine salt comprises nicotine sorbate.
32. The method of any one of embodiments 1-18, wherein said nicotine salt comprises nicotine laurate.
33. The method of any one of embodiments 1-18, wherein said nicotine salt comprises nicotine levulinate.
34. The method of any one of embodiments 1-18, wherein said nicotine salt comprises nicotine benzoate.
35. The method of any one of embodiments 1-34, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
36. The method of any one of embodiments 1-34, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
37. The method of any one of embodiments 1-34, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
38. The method of any one of embodiments 1-34, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
39. The method of any one of embodiments 1-38, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
40. The method of any one of embodiments 1-38, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
41. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
42. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
43. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
44. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
45. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
46. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
47. The method of any one of embodiments 1-40, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
48. The method of any one of embodiments 1-47, wherein the formulation further comprises a flavorant.
49. The method of any one of embodiments 1-48, wherein the formulation is non-corrosive to an electronic cigarette.
50. The method of any one of embodiments 1-49, wherein the acid is stable at and below operating temperature or about 200° C.
51. The method of any one of embodiments 1-50, wherein the acid does not decompose at and below operating temperature or about 200° C.
52. The method of any one of embodiments 1-51, wherein the acid does not oxidize at and below operating temperature or about 200° C.
53. The method of any one of embodiments 1-52, wherein the formulation is non-corrosive to the electronic cigarette.
54. The method of any one of embodiments 1-53, wherein the formulation is non-toxic to a user of the electronic cigarette.
55. The method of any one of embodiments 1-54, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
56. The method of embodiment 55, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
57. A method of delivering nicotine to the blood of a user, said method comprising providing an aerosol that is inhaled by the user from an electronic cigarette that comprises a nicotine salt formulation wherein providing the aerosol comprises the electronic cigarette heating the formulation thereby generating the aerosol, wherein the aerosol is effective in delivering a level of nicotine in the blood of the user that is at least 5 ng/mL at about 1.5 minutes after a first puff of ten puffs of the aerosol, each puff taken at 30 second intervals.
58. The method of embodiment 54, wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
59. The method of embodiment 54, wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
60. The method of embodiment 54, wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
61. The method of any one of embodiments 57-60, wherein the heating of the formulation is at a temperature from 150° C. to 250° C.
62. The method of any one of embodiments 57-60, wherein the heating of the formulation is at a temperature from 180° C. to 220° C.
63. The method of any one of embodiments 57-60, wherein the heating of the formulation is at a temperature of about 200° C.
64. The method of embodiment 54, wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than the operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point; and the operating temperature is 200° C.
65. The method of any one of embodiments 57-64, wherein the Cmax is over 10 ng/mL on average.
66. The method of any one of embodiments 57-64, wherein the Cmax is over 11 ng/mL on average.
67. The method of any one of embodiments 57-64, wherein the Cmax is between 10 ng/mL and 16 ng/mL on average.
68. The method of any one of embodiments 57-64, wherein the Cmax is between 11 ng/mL and 15 ng/mL on average.
69. The method of any one of embodiments 57-64, wherein the Cmax is between 11 ng/mL and 14 ng/mL on average.
70. The method of any one of embodiments 57-69, wherein the Tmax under 10 minutes on average.
71. The method of any one of embodiments 57-69, wherein the Tmax is under 9 minutes on average.
72. The method of any one of embodiments 57-69, wherein the Tmax is under 8 minutes on average.
73. The method of any one of embodiments 57-69, wherein the Tmax is under 7 minutes on average.
74. The method of any one of embodiments 54-63, wherein the Tmax is from 3 minutes to 10 minutes on average.
75. The method of any one of embodiments 57-69, wherein the Tmax is from 3 minutes to 7.5 minutes on average.
76. The method of any one of embodiments 57-75, wherein the aerosol comprises condensate of the nicotine salt.
77. The method of any one of embodiments 57-75, wherein the aerosol comprises condensate of freebase nicotine.
78. The method of any one of embodiments 57-75, wherein the aerosol comprises condensate of freebase nicotine and condensate of the carrier.
79. The method of any one of embodiments 57-75, wherein the aerosol comprises condensate of freebase nicotine and condensate of the acid.
80. The method of any one of embodiments 57-79, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 5 microns.
81. The method of any one of embodiments 57-79, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 1 or 2 microns.
82. The method of any one of embodiments 57-79, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 0.7 microns.
83. The method of any one of embodiments 57-79, wherein the aerosol comprises condensate in particle sizes from about 0.3 microns to about 0.4 microns.
84. The method of any one of embodiments 57-83, wherein the acid is a carboxylic acid.
85. The method of any one of embodiments 57-83, wherein the acid used to form said nicotine salt is an organic acid.
86. The method of embodiment 85, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
87. The method of embodiment 85, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
88. The method of any one of embodiments 57-83, wherein the acid used to form the nicotine salt is salicylic acid.
89. The method of any one of embodiments 57-83, wherein the acid used to form the nicotine salt is benzoic acid.
90. The method of any one of embodiments 57-83, wherein the acid used to form the nicotine salt is pyruvic acid.
91. The method of any one of embodiments 57-83, wherein the acid used to form the nicotine salt is sorbic acid.
92. The method of any one of embodiments 57-83, wherein the acid used to form the nicotine salt is lauric acid.
93. The method of any one of embodiments 57-83, wherein the acid used to form the nicotine salt is levulinic acid.
94. The method of any one of embodiments 57-83, wherein said nicotine salt comprises nicotine pyruvate.
95. The method of any one of embodiments 57-83, wherein said nicotine salt comprises nicotine salicylate.
96. The method of any one of embodiments 57-83, wherein said nicotine salt comprises nicotine sorbate.
97. The method of any one of embodiments 57-83, wherein said nicotine salt comprises nicotine laurate.
98. The method of any one of embodiments 57-83, wherein said nicotine salt comprises nicotine levulinate.
99. The method of any one of embodiments 57-83, wherein said nicotine salt comprises nicotine benzoate.
100. The method of any one of embodiments 57-99, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
101. The method of any one of embodiments 57-99, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
102. The method of any one of embodiments 57-99, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
103. The method of any one of embodiments 57-99, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
104. The method of any one of embodiments 57-103, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
105. The method of any one of embodiments 57-103, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
106. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
107. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
108. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
109. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
110. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
111. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
112. The method of any one of embodiments 57-105, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
113. The method of any one of embodiments 57-112, wherein the formulation further comprises a flavorant.
114. The method of any one of embodiments 57-113, wherein the formulation is non-corrosive to an electronic cigarette.
115. The method of any one of embodiments 57-114, wherein the acid is stable at and below operating temperature or about 200° C.
116. The method of any one of embodiments 57-115, wherein the acid does not decompose at and below operating temperature or about 200° C.
117. The method of any one of embodiments 57-116, wherein the acid does not oxidize at and below operating temperature or about 200° C.
118. The method of any one of embodiments 57-117, wherein the formulation is non-corrosive to the electronic cigarette.
119. The method of any one of embodiments 57-118, wherein the formulation is non-toxic to a user of the electronic cigarette.
120. The method of any one of embodiments 57-119, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
121. The method of embodiment 120, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
122. A nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
123. A nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
124. A nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
125. A nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
126. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-124, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 150° C. to 250° C.
127. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-124, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 180° C. to 220° C.
128. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-124, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature of about 200° C.
129. The nicotine salt liquid formulation in the electronic cigarette of embodiment 125, wherein the operating temperature is from 150° C. to 250° C.
130. The nicotine salt liquid formulation in the electronic cigarette of embodiment 125, wherein the operating temperature is from 180° C. to 220° C.
131. The nicotine salt liquid formulation in the electronic cigarette of embodiment 125, wherein the operating temperature is about 200° C.
132. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid is a carboxylic acid.
133. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form said nicotine salt is an organic acid.
134. The nicotine salt liquid formulation in the electronic cigarette of embodiment 133, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
135. The nicotine salt liquid formulation in the electronic cigarette of embodiment 133, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
136. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form the nicotine salt is salicylic acid.
137. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form the nicotine salt is benzoic acid.
138. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form the nicotine salt is pyruvic acid.
139. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form the nicotine salt is sorbic acid.
140. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form the nicotine salt is lauric acid.
141. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein the acid used to form the nicotine salt is levulinic acid.
142. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein said nicotine salt comprises nicotine pyruvate.
143. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein said nicotine salt comprises nicotine salicylate.
144. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein said nicotine salt comprises nicotine sorbate.
145. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein said nicotine salt comprises nicotine laurate.
146. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein said nicotine salt comprises nicotine levulinate.
147. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-131, wherein said nicotine salt comprises nicotine benzoate.
148. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-147, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
149. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-147, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
150. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-147, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
151. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-147, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
152. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-151, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
153. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-151, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
154. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
155. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
156. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
157. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
158. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
159. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
160. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-153, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
161. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-160, wherein the formulation further comprises a flavorant.
162. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-161, wherein the formulation is non-corrosive to an electronic cigarette.
163. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-162, wherein the acid is stable at and below operating temperature or about 200° C.
164. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-163, wherein the acid does not decompose at and below operating temperature or about 200° C.
165. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-164, wherein the acid does not oxidize at and below operating temperature or about 200° C.
166. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-165, wherein the formulation is non-corrosive to the electronic cigarette.
167. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-166, wherein the formulation is non-toxic to a user of the electronic cigarette.
168. The nicotine salt liquid formulation in the electronic cigarette of any one of embodiments 122-167 further comprising one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
169. The nicotine salt liquid formulation in the electronic cigarette of embodiment 168, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
170. A nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
171. A nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
172. A nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
173. A nicotine salt liquid formulation for generating an inhalable aerosol upon heating in the electronic cigarette, the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
174. The nicotine salt liquid formulation of any one of embodiments 170-172, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 150° C. to 250° C.
175. The nicotine salt liquid formulation of any one of embodiments 170-172, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 180° C. to 220° C.
176. The nicotine salt liquid formulation of any one of embodiments 170-172, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature of about 200° C.
177. The nicotine salt liquid formulation of embodiment 173, wherein the operating temperature is from 150° C. to 250° C.
178. The nicotine salt liquid formulation of embodiment 173, wherein the operating temperature is from 180° C. to 220° C.
179. The nicotine salt liquid formulation of embodiment 173, wherein the operating temperature is about 200° C.
180. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid is a carboxylic acid.
181. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid used to form said nicotine salt is an organic acid.
182. The nicotine salt liquid formulation of embodiment 181, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
183. The nicotine salt liquid formulation of embodiment 181, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
184. The liquid formulation of any one of embodiments 170-179, wherein the acid used to form the nicotine salt is salicylic acid.
185. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid used to form the nicotine salt is benzoic acid.
186. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid used to form the nicotine salt is pyruvic acid.
187. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid used to form the nicotine salt is sorbic acid.
188. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid used to form the nicotine salt is lauric acid.
189. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein the acid used to form the nicotine salt is levulinic acid.
190. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein said nicotine salt comprises nicotine pyruvate.
191. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein said nicotine salt comprises nicotine salicylate.
192. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein said nicotine salt comprises nicotine sorbate.
193. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein said nicotine salt comprises nicotine laurate.
194. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein said nicotine salt comprises nicotine levulinate.
195. The nicotine salt liquid formulation of any one of embodiments 170-179, wherein said nicotine salt comprises nicotine benzoate.
196. The nicotine salt liquid formulation of any one of embodiments 170-195, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
197. The nicotine salt liquid formulation of any one of embodiments 170-195, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
198. The nicotine salt liquid formulation of any one of embodiments 170-195, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
199. The nicotine salt liquid formulation of any one of embodiments 170-195, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
200. The nicotine salt liquid formulation of any one of embodiments 170-199, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
201. The nicotine salt liquid formulation of any one of embodiments 170-199, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
202. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
203. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
204. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
205. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
206. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
207. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
208. The nicotine salt liquid formulation of any one of embodiments 170-201, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
209. The nicotine salt liquid formulation of any one of embodiments 170-208, wherein the formulation further comprises a flavorant.
210. The nicotine salt liquid formulation of any one of embodiments 170-209, wherein the formulation is non-corrosive to an electronic cigarette.
211. The nicotine salt liquid formulation of any one of embodiments 170-210, wherein the acid is stable at and below operating temperature or about 200° C.
212. The nicotine salt liquid formulation of any one of embodiments 170-211, wherein the acid does not decompose at and below operating temperature or about 200° C.
213. The nicotine salt liquid formulation of any one of embodiments 170-212, wherein the acid does not oxidize at and below operating temperature or about 200° C.
214. The nicotine salt liquid formulation of any one of embodiments 170-213, wherein the formulation is non-corrosive to the electronic cigarette.
215. The nicotine salt liquid formulation of any one of embodiments 170-214, wherein the formulation is non-toxic to a user of the electronic cigarette.
216. The nicotine salt liquid formulation of any one of embodiments 170-215, further comprising one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
217. The nicotine salt liquid formulation of embodiment 216, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
218. A nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
219. A nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
220. A nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
221. A nicotine salt liquid formulation for use in an electronic cigarette the nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
222. The nicotine salt liquid formulation of any one of embodiments 218-220, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 150° C. to 250° C.
223. The nicotine salt liquid formulation of any one of embodiments 218-220, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 180° C. to 220° C.
224. The nicotine salt liquid formulation of any one of embodiments 218-220, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature of about 200° C.
225. The nicotine salt liquid formulation of embodiment 221, wherein the operating temperature is from 150° C. to 250° C.
226. The nicotine salt liquid formulation of embodiment 221, wherein the operating temperature is from 180° C. to 220° C.
227. The nicotine salt liquid formulation of embodiment 221, wherein the operating temperature is about 200° C.
228. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid is a carboxylic acid.
229. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid used to form said nicotine salt is an organic acid.
230. The nicotine salt liquid formulation of embodiment 229, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
231. The nicotine salt liquid formulation of embodiment 229, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
232. The liquid formulation of any one of embodiments 218-227, wherein the acid used to form the nicotine salt is salicylic acid.
233. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid used to form the nicotine salt is benzoic acid.
234. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid used to form the nicotine salt is pyruvic acid.
235. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid used to form the nicotine salt is sorbic acid.
236. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid used to form the nicotine salt is lauric acid.
237. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein the acid used to form the nicotine salt is levulinic acid.
238. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein said nicotine salt comprises nicotine pyruvate.
239. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein said nicotine salt comprises nicotine salicylate.
240. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein said nicotine salt comprises nicotine sorbate.
241. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein said nicotine salt comprises nicotine laurate.
242. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein said nicotine salt comprises nicotine levulinate.
243. The nicotine salt liquid formulation of any one of embodiments 218-227, wherein said nicotine salt comprises nicotine benzoate.
244. The nicotine salt liquid formulation of any one of embodiments 218-243, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
245. The nicotine salt liquid formulation of any one of embodiments 218-243, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
246. The nicotine salt liquid formulation of any one of embodiments 218-243, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
247. The nicotine salt liquid formulation of any one of embodiments 218-243, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
248. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
249. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
250. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
251. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
252. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
253. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
254. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
255. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
256. The nicotine salt liquid formulation of any one of embodiments 218-247, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
257. The nicotine salt liquid formulation of any one of embodiments 218-256, wherein the formulation further comprises a flavorant.
258. The nicotine salt liquid formulation of any one of embodiments 218-257, wherein the formulation is non-corrosive to an electronic cigarette.
259. The nicotine salt liquid formulation of any one of embodiments 218-258, wherein the acid is stable at and below operating temperature or about 200° C.
260. The nicotine salt liquid formulation of any one of embodiments 218-259, wherein the acid does not decompose at and below operating temperature or about 200° C.
261. The nicotine salt liquid formulation of any one of embodiments 218-260, wherein the acid does not oxidize at and below operating temperature or about 200° C.
262. The nicotine salt liquid formulation of any one of embodiments 218-261, wherein the formulation is non-corrosive to the electronic cigarette.
263. The nicotine salt liquid formulation of any one of embodiments 218-262, wherein the formulation is non-toxic to a user of the electronic cigarette.
264. The nicotine salt liquid formulation of any one of embodiments 218-263, further comprising one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
265. The nicotine salt liquid formulation of embodiment 264, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
266. Use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C., and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
267. Use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C., and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
268. Use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point, and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
269. Use of a nicotine salt formulation for delivery of nicotine to the blood of a user from an electronic cigarette, wherein the nicotine salt formulation in the electronic cigarette is heated to form an aerosol which delivers a level of nicotine in the blood of the user that is at least 5 ng/mL at about 1.5 minutes after a first puff of ten puffs of the aerosol, each puff taken at 30 second intervals.
270. Use of a nicotine salt formulation for delivery of nicotine to a user from an electronic cigarette wherein the nicotine salt formulation comprises a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point, and the nicotine salt formulation is heated by the electronic cigarette to generate an aerosol inhalable by the user.
271. The use of any one of embodiments 266-269, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature is from 150° C. to 250° C.
272. The use of any one of embodiments 266-269, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature is from 180° C. to 220° C.
273. The use of any one of embodiments 266-269, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature is about 200° C.
274. The use of embodiment 270, wherein the operating temperature is from 150° C. to 250° C.
275. The use of embodiment 270, wherein the operating temperature is from 180° C. to 220° C.
276. The use of embodiment 270, wherein the operating temperature is about 200° C.
277. The use of any one of embodiments 266-276, wherein the aerosol comprises condensate of the nicotine salt.
278. The use of any one of embodiments 266-276, wherein the aerosol comprises condensate of freebase nicotine.
279. The use of any one of embodiments 266-276, wherein the aerosol comprises condensate of freebase nicotine and condensate of the carrier.
280. The use of any one of embodiments 266-276, wherein the aerosol comprises condensate of freebase nicotine and condensate of the acid.
281. The use of any one of embodiments 266-280, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 5 microns.
282. The use of any one of embodiments 266-280, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 1 or 2 microns.
283. The use of any one of embodiments 266-280, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 0.7 microns.
284. The use of any one of embodiments 266-280, wherein the aerosol comprises condensate in particle sizes from about 0.3 microns to about 0.4 microns.
285. The use of any one of embodiments 266-284, wherein the acid is a carboxylic acid.
286. The use of any one of embodiments 266-284, wherein the acid used to form said nicotine salt is an organic acid.
287. The use of embodiment 286, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
288. The use of embodiment 286, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
289. The use of any one of embodiments 266-284, wherein the acid used to form the nicotine salt is salicylic acid.
290. The use of any one of embodiments 266-284, wherein the acid used to form the nicotine salt is benzoic acid.
291. The use of any one of embodiments 266-284, wherein the acid used to form the nicotine salt is pyruvic acid.
292. The use of any one of embodiments 266-284, wherein the acid used to form the nicotine salt is sorbic acid.
293. The use of any one of embodiments 266-284, wherein the acid used to form the nicotine salt is lauric acid.
294. The use of any one of embodiments 266-284, wherein the acid used to form the nicotine salt is levulinic acid.
295. The use of any one of embodiments 266-284, wherein said nicotine salt comprises nicotine pyruvate.
296. The use of any one of embodiments 266-284, wherein said nicotine salt comprises nicotine salicylate.
297. The use of any one of embodiments 266-284, wherein said nicotine salt comprises nicotine sorbate.
298. The use of any one of embodiments 266-284, wherein said nicotine salt comprises nicotine laurate.
299. The use of any one of embodiments 266-284, wherein said nicotine salt comprises nicotine levulinate.
300. The use of any one of embodiments 266-284, wherein said nicotine salt comprises nicotine benzoate.
301. The use of any one of embodiments 266-300, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
302. The use of any one of embodiments 266-300, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
303. The use of any one of embodiments 266-300, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
304. The use of any one of embodiments 266-300, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
305. The use of any one of embodiments 266-304, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
306. The use of any one of embodiments 266-304, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
307. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
308. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
309. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
310. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
311. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
312. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
313. The use of any one of embodiments 266-306, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
314. The use of any one of embodiments 266-313, wherein the formulation further comprises a flavorant.
315. The use of any one of embodiments 266-314, wherein the formulation is non-corrosive to an electronic cigarette.
316. The use of any one of embodiments 266-315, wherein the acid is stable at and below operating temperature or about 200° C.
317. The use of any one of embodiments 266-316, wherein the acid does not decompose at and below operating temperature or about 200° C.
318. The use of any one of embodiments 266-317, wherein the acid does not oxidize at and below operating temperature or about 200° C.
319. The use of any one of embodiments 266-318, wherein the formulation is non-corrosive to the electronic cigarette.
320. The use of any one of embodiments 266-319, wherein the formulation is non-toxic to a user of the electronic cigarette.
321. The use of any one of embodiments 266-320, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
322. The use of embodiment 321, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid
323. A cartomizer for an electronic cigarette comprising:
324. A cartomizer for an electronic cigarette comprising:
325. A cartomizer for an electronic cigarette comprising:
326. A cartomizer for an electronic cigarette comprising:
327. The cartomizer of any one of embodiments 323-325, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 150° C. to 250° C.
328. The cartomizer of any one of embodiments 323-325, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 180° C. to 220° C.
329. The cartomizer of any one of embodiments 323-325, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature of about 200° C.
330. The cartomizer of embodiment 326, wherein the operating temperature is from 150° C. to 250° C.
331. The cartomizer of embodiment 326, wherein the operating temperature is from 180° C. to 220° C.
332. The cartomizer of embodiment 326, wherein the operating temperature is about 200° C.
333. The cartomizer of any one of embodiments 323-332, wherein the cartomizer further comprises a mouthpiece.
334. The cartomizer of any one of embodiments 323-333, wherein the acid is a carboxylic acid.
335. The cartomizer of any one of embodiments 323-333, wherein the acid used to form said nicotine salt is an organic acid.
336. The cartomizer of embodiment 335, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
337. The cartomizer of embodiment 335, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
338. The cartomizer of any one of embodiments 323-333, wherein the acid used to form the nicotine salt is salicylic acid.
339. The cartomizer of any one of embodiments 323-333, wherein the acid used to form the nicotine salt is benzoic acid.
340. The cartomizer of any one of embodiments 323-333, wherein the acid used to form the nicotine salt is pyruvic acid.
341. The cartomizer of any one of embodiments 323-333, wherein the acid used to form the nicotine salt is sorbic acid.
342. The cartomizer of any one of embodiments 323-333, wherein the acid used to form the nicotine salt is lauric acid.
343. The cartomizer of any one of embodiments 323-333, wherein the acid used to form the nicotine salt is levulinic acid.
344. The cartomizer of any one of embodiments 323-333, wherein said nicotine salt comprises nicotine pyruvate.
345. The cartomizer of any one of embodiments 323-333, wherein said nicotine salt comprises nicotine salicylate.
346. The cartomizer of any one of embodiments 323-333, wherein said nicotine salt comprises nicotine sorbate.
347. The cartomizer of any one of embodiments 323-333, wherein said nicotine salt comprises nicotine laurate.
348. The cartomizer of any one of embodiments 323-333, wherein said nicotine salt comprises nicotine levulinate.
349. The cartomizer of any one of embodiments 323-333, wherein said nicotine salt comprises nicotine benzoate.
350. The cartomizer of any one of embodiments 323-349, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
351. The cartomizer of any one of embodiments 323-349, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
352. The cartomizer of any one of embodiments 323-349, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
353. The cartomizer of any one of embodiments 323-349, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
354. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
355. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
356. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
357. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
358. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
359. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
360. The cartomizer of any one of embodiments 323-353, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
361. The cartomizer of any one of embodiments 323-360, wherein the electronic cigarette is configured to generate an aerosol inhalable by a user.
362. The cartomizer of embodiment 361, wherein the aerosol comprises condensate of the nicotine salt.
363. The cartomizer of embodiment 361, wherein the aerosol comprises condensate of freebase nicotine.
364. The cartomizer of embodiment 361, wherein the aerosol comprises condensate of freebase nicotine and condensate of the carrier.
365. The cartomizer of embodiment 361, wherein the aerosol comprises condensate of freebase nicotine and condensate of the acid.
366. The cartomizer of any one of embodiments 361-365, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 5 microns.
367. The cartomizer of any one of embodiments 361-365, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 1 or 2 microns.
368. The cartomizer of any one of embodiments 361-365, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 0.7 microns.
369. The cartomizer of any one of embodiments 361-365, wherein the aerosol comprises condensate in particle sizes from about 0.3 microns to about 0.4 microns.
370. The cartomizer of any one of embodiments 361-369, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
371. The cartomizer of any one of embodiments 361-369, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
372. The cartomizer of any one of embodiments 323-371, wherein the formulation further comprises a flavorant.
373. The cartomizer of any one of embodiments 323-372, wherein the formulation is non-corrosive to an electronic cigarette.
374. The cartomizer of any one of embodiments 323-373, wherein the acid is stable at and below operating temperature or about 200° C.
375. The cartomizer of any one of embodiments 323-374, wherein the acid does not decompose at and below operating temperature or about 200° C.
376. The cartomizer of any one of embodiments 323-375, wherein the acid does not oxidize at and below operating temperature or about 200° C.
377. The cartomizer of any one of embodiments 323-376, wherein the formulation is non-corrosive to the electronic cigarette.
378. The cartomizer of any one of embodiments 323-377, wherein the formulation is non-toxic to a user of the electronic cigarette.
379. The cartomizer of any one of embodiments 323-378, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
380. The cartomizer of embodiment 379, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
381. An electronic cigarette for generating an inhalable aerosol comprising
382. An electronic cigarette for generating an inhalable aerosol comprising
383. An electronic cigarette for generating an inhalable aerosol comprising
384. An electronic cigarette for generating an inhalable aerosol comprising
385. The electronic cigarette of any one of embodiments 381-384, wherein the heater comprises a heater chamber, a fluid wick, and a resistive heating element in contact with the fluid wick.
386. The electronic cigarette of any one of embodiments 381-384, wherein the mouthpiece, the heater and the fluid storage compartment form a cartomizer separable from the battery.
387. The electronic cigarette of any one of embodiments 381-384, wherein the heater and the fluid storage compartment form a cartomizer separable from the battery and the mouthpiece.
388. The electronic cigarette of any one of embodiments 381-384, wherein the fluid storage compartment is separable from the heater, the battery and the mouthpiece.
389. The electronic cigarette of any one of embodiments 381-383, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 150° C. to 250° C.
390. The electronic cigarette of any one of embodiments 381-383, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature from 180° C. to 220° C.
391. The electronic cigarette of any one of embodiments 381-383, wherein the electronic cigarette heats the nicotine salt formulation to an operating temperature of about 200° C.
392. The electronic cigarette of embodiment 384, wherein the operating temperature is from 150° C. to 250° C.
393. The electronic cigarette of embodiment 384, wherein the operating temperature is from 180° C. to 220° C.
394. The electronic cigarette of embodiment 384, wherein the operating temperature is about 200° C.
395. The electronic cigarette of any one of embodiments 381-394, wherein the aerosol comprises condensate of the nicotine salt.
396. The electronic cigarette of any one of embodiments 381-394, wherein the aerosol comprises condensate of freebase nicotine.
397. The electronic cigarette of any one of embodiments 381-394, wherein the aerosol comprises condensate of freebase nicotine and condensate of the carrier.
398. The electronic cigarette of any one of embodiments 381-394, wherein the aerosol comprises condensate of freebase nicotine and condensate of the acid.
399. The electronic cigarette of any one of embodiments 381-398, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 5 microns.
400. The electronic cigarette of any one of embodiments 381-398, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 1 or 2 microns.
401. The electronic cigarette of any one of embodiments 381-398, wherein the aerosol comprises condensate in particle sizes from about 0.1 microns to about 0.7 microns.
402. The electronic cigarette of any one of embodiments 381-398, wherein the aerosol comprises condensate in particle sizes from about 0.3 microns to about 0.4 microns.
403. The electronic cigarette of any one of embodiments 381-402, wherein the acid is a carboxylic acid.
404. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form said nicotine salt is an organic acid.
405. The electronic cigarette of embodiment 404, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
406. The electronic cigarette of embodiment 404, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
407. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form the nicotine salt is salicylic acid.
408. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form the nicotine salt is benzoic acid.
409. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form the nicotine salt is pyruvic acid.
410. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form the nicotine salt is sorbic acid.
411. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form the nicotine salt is lauric acid.
412. The electronic cigarette of any one of embodiments 381-402, wherein the acid used to form the nicotine salt is levulinic acid.
413. The electronic cigarette of any one of embodiments 381-402, wherein said nicotine salt comprises nicotine pyruvate.
414. The electronic cigarette of any one of embodiments 381-402, wherein said nicotine salt comprises nicotine salicylate.
415. The electronic cigarette of any one of embodiments 381-402, wherein said nicotine salt comprises nicotine sorbate.
416. The electronic cigarette of any one of embodiments 381-402, wherein said nicotine salt comprises nicotine laurate.
417. The electronic cigarette of any one of embodiments 381-402, wherein said nicotine salt comprises nicotine levulinate.
418. The electronic cigarette of any one of embodiments 381-402, wherein said nicotine salt comprises nicotine benzoate.
419. The electronic cigarette of any one of embodiments 381-419, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
420. The electronic cigarette of any one of embodiments 381-419, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
421. The electronic cigarette of any one of embodiments 381-419, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
422. The electronic cigarette of any one of embodiments 381-419, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
423. The electronic cigarette of any one of embodiments 381-422, wherein the nicotine salt is in an amount that forms about 0.5% to about 20% nicotine in the inhalable aerosol.
424. The electronic cigarette of any one of embodiments 381-422, wherein the nicotine salt is in an amount that forms about 1% to about 20% nicotine in the inhalable aerosol.
425. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
426. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
427. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
428. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
429. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
430. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
431. The electronic cigarette of any one of embodiments 381-424, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
432. The electronic cigarette of any one of embodiments 381-431, wherein the formulation further comprises a flavorant.
433. The electronic cigarette of any one of embodiments 381-432, wherein the formulation is non-corrosive to an electronic cigarette.
434. The electronic cigarette of any one of embodiments 381-433, wherein the acid is stable at and below operating temperature or about 200° C.
435. The electronic cigarette of any one of embodiments 381-434, wherein the acid does not decompose at and below operating temperature or about 200° C.
436. The electronic cigarette of any one of embodiments 381-435, wherein the acid does not oxidize at and below operating temperature or about 200° C.
437. The electronic cigarette of any one of embodiments 381-436, wherein the formulation is non-corrosive to the electronic cigarette.
438. The electronic cigarette of any one of embodiments 381-437, wherein the formulation is non-toxic to a user of the electronic cigarette.
439. The electronic cigarette of any one of embodiments 381-438, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
440. The electronic cigarette of embodiment 439, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
441. A cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
442. A cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
443. A cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
444. A cartridge in an electronic cigarette comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
445. The cartridge of any one of embodiments 441-444, wherein the cartridge is separable from the electronic cigarette.
446. The cartridge of any one of embodiments 441-445, wherein the acid is a carboxylic acid.
447. The cartridge of any one of embodiments 441-445, wherein the acid used to form said nicotine salt is an organic acid.
448. The cartridge of embodiment 447, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
449. The cartridge of embodiment 447, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
450. The cartridge of any one of embodiments 441-445, wherein the acid used to form the nicotine salt is salicylic acid.
451. The cartridge of any one of embodiments 441-445, wherein the acid used to form the nicotine salt is benzoic acid.
452. The cartridge of any one of embodiments 441-445, wherein the acid used to form the nicotine salt is pyruvic acid.
453. The cartridge of any one of embodiments 441-445, wherein the acid used to form the nicotine salt is sorbic acid.
454. The cartridge of any one of embodiments 441-445, wherein the acid used to form the nicotine salt is lauric acid.
455. The cartridge of any one of embodiments 441-445, wherein the acid used to form the nicotine salt is levulinic acid.
456. The cartridge of any one of embodiments 441-445, wherein said nicotine salt comprises nicotine pyruvate.
457. The cartridge of any one of embodiments 441-445, wherein said nicotine salt comprises nicotine salicylate.
458. The cartridge of any one of embodiments 441-445, wherein said nicotine salt comprises nicotine sorbate.
459. The cartridge of any one of embodiments 441-445, wherein said nicotine salt comprises nicotine laurate.
460. The cartridge of any one of embodiments 441-445, wherein said nicotine salt comprises nicotine levulinate.
461. The cartridge of any one of embodiments 441-445, wherein said nicotine salt comprises nicotine benzoate.
462. The cartridge of any one of embodiments 441-461, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
463. The cartridge of any one of embodiments 441-461, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
464. The cartridge of any one of embodiments 441-461, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
465. The cartridge of any one of embodiments 441-461, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
466. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
467. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
468. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
469. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
470. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
471. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
472. The cartridge of any one of embodiments 441-465, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
473. The cartridge of any one of embodiments 441-472, wherein the formulation further comprises a flavorant.
474. The cartridge of any one of embodiments 441-473, wherein the formulation is non-corrosive to an electronic cigarette.
475. The cartridge of any one of embodiments 441-474, wherein the acid is stable at and below operating temperature or about 200° C.
476. The cartridge of any one of embodiments 441-475, wherein the acid does not decompose at and below operating temperature or about 200° C.
477. The cartridge of any one of embodiments 441-476, wherein the acid does not oxidize at and below operating temperature or about 200° C.
478. The cartridge of any one of embodiments 441-477, wherein the formulation is non-corrosive to the electronic cigarette.
479. The cartridge of any one of embodiments 441-478, wherein the formulation is non-toxic to a user of the electronic cigarette.
480. The cartridge of any one of embodiments 441-479, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
481. The cartridge of embodiment 480, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
482. A kit comprising:
483. A kit comprising:
484. A kit comprising:
485. A kit comprising:
486. The kit of any one of embodiments 482-485, wherein the acid is a carboxylic acid.
487. The kit of any one of embodiments 482-485, wherein the acid used to form said nicotine salt is an organic acid.
488. The kit of embodiment 487, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
489. The kit of embodiment 487, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
490. The kit of any one of embodiments 482-485, wherein the acid used to form the nicotine salt is salicylic acid.
491. The kit of any one of embodiments 482-485, wherein the acid used to form the nicotine salt is benzoic acid.
492. The kit of any one of embodiments 482-485, wherein the acid used to form the nicotine salt is pyruvic acid.
493. The kit of any one of embodiments 482-485, wherein the acid used to form the nicotine salt is sorbic acid.
494. The kit of any one of embodiments 482-485, wherein the acid used to form the nicotine salt is lauric acid.
495. The kit of any one of embodiments 482-485, wherein the acid used to form the nicotine salt is levulinic acid.
496. The kit of any one of embodiments 482-485, wherein said nicotine salt comprises nicotine pyruvate.
497. The kit of any one of embodiments 482-485, wherein said nicotine salt comprises nicotine salicylate.
498. The kit of any one of embodiments 482-485, wherein said nicotine salt comprises nicotine sorbate.
499. The kit of any one of embodiments 482-485, wherein said nicotine salt comprises nicotine laurate.
500. The kit of any one of embodiments 482-485, wherein said nicotine salt comprises nicotine levulinate.
501. The kit of any one of embodiments 482-485, wherein said nicotine salt comprises nicotine benzoate.
502. The kit of any one of embodiments 482-501, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
503. The kit of any one of embodiments 482-501, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
504. The kit of any one of embodiments 482-501, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
505. The kit of any one of embodiments 482-501, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
506. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
507. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
508. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
509. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
510. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
511. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
512. The kit of any one of embodiments 482-505, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
513. The kit of any one of embodiments 482-512, wherein the formulation further comprises a flavorant.
514. The kit of any one of embodiments 482-513, wherein the formulation is non-corrosive to an electronic cigarette.
515. The kit of any one of embodiments 482-514, wherein the acid is stable at and below operating temperature or about 200° C.
516. The kit of any one of embodiments 482-515, wherein the acid does not decompose at and below operating temperature or about 200° C.
517. The kit of any one of embodiments 482-516, wherein the acid does not oxidize at and below operating temperature or about 200° C.
518. The kit of any one of embodiments 482-517, wherein the formulation is non-corrosive to the electronic cigarette.
519. The kit of any one of embodiments 482-518, wherein the formulation is non-toxic to a user of the electronic cigarette.
520. The kit of any one of embodiments 482-519, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
521. The kit of embodiment 520, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
522. A cartridge comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure>20 mmHg at 200° C.
523. A cartridge comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure of about 20 to 200 mmHg at 200° C.
524. A cartridge comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point<160° C., a boiling point>160° C., and at least a 50-degree difference between the melting point and the boiling point.
525. A cartridge comprising a fluid storage compartment, wherein the fluid storage compartment stores a nicotine salt liquid formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is further characterized by a melting point at least 40 degrees lower than an operating temperature of the electronic cigarette, a boiling point no more than 40 degrees lower than the operating temperature of the electronic cigarette, and at least a 50-degree difference between the melting point and the boiling point.
526. The cartridge of any one of embodiments 523-526, wherein the cartridge can be connected to an electronic cigarette.
527. The cartridge of any one of embodiments 523-527, wherein the acid is a carboxylic acid.
528. The cartridge of any one of embodiments 523-527, wherein the acid used to form said nicotine salt is an organic acid.
529. The cartridge of embodiment 529, wherein the organic acid is monocarboxylic acid, aromatic acid, or keto acid.
530. The cartridge of embodiment 529, wherein the organic acid is formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, citric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, phenylacetic acid, benzoic acid, pyruvic acid, levulinic acid, tartaric acid, lactic acid, malonic acid, succinic acid, fumaric acid, finnaric acid, gluconic acid, saccharic acid, salicylic acid, sorbic acid, malonic acid, or malic acid.
531. The cartridge of any one of embodiments 523-527, wherein the acid used to form the nicotine salt is salicylic acid.
532. The cartridge of any one of embodiments 523-527, wherein the acid used to form the nicotine salt is benzoic acid.
533. The cartridge of any one of embodiments 523-527, wherein the acid used to form the nicotine salt is pyruvic acid.
534. The cartridge of any one of embodiments 523-527, wherein the acid used to form the nicotine salt is sorbic acid.
535. The cartridge of any one of embodiments 523-527, wherein the acid used to form the nicotine salt is lauric acid.
536. The cartridge of any one of embodiments 523-527, wherein the acid used to form the nicotine salt is levulinic acid.
537. The cartridge of any one of embodiments 523-527, wherein said nicotine salt comprises nicotine pyruvate.
538. The cartridge of any one of embodiments 523-527, wherein said nicotine salt comprises nicotine salicylate.
539. The cartridge of any one of embodiments 523-527, wherein said nicotine salt comprises nicotine sorbate.
540. The cartridge of any one of embodiments 523-527, wherein said nicotine salt comprises nicotine laurate.
541. The cartridge of any one of embodiments 523-527, wherein said nicotine salt comprises nicotine levulinate.
542. The cartridge of any one of embodiments 523-527, wherein said nicotine salt comprises nicotine benzoate.
543. The cartridge of any one of embodiments 523-543, wherein the liquid carrier comprises glycerol, propylene glycol, trimethylene glycol, water, ethanol or combinations thereof.
544. The cartridge of any one of embodiments 523-543, wherein the liquid carrier comprises propylene glycol and vegetable glycerin.
545. The cartridge of any one of embodiments 523-543, wherein the liquid carrier comprises 20% to 50% of propylene glycol and 80% to 50% of vegetable glycerin.
546. The cartridge of any one of embodiments 523-543, wherein the liquid carrier comprises 30% propylene glycol and 70% vegetable glycerin.
547. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 25% (w/w).
548. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 20% (w/w).
549. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 18% (w/w).
550. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 1% (w/w) to about 15% (w/w).
551. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 4% (w/w) to about 12% (w/w).
552. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 4% (w/w).
553. The cartridge of any one of embodiments 523-547, wherein the liquid formulation has a nicotine concentration of about 2% (w/w).
554. The cartridge of any one of embodiments 523-553, wherein the formulation further comprises a flavorant.
555. The cartridge of any one of embodiments 523-554, wherein the formulation is non-corrosive to an electronic cigarette.
556. The cartridge of any one of embodiments 523-555, wherein the acid is stable at and below operating temperature or about 200° C.
557. The cartridge of any one of embodiments 523-556, wherein the acid does not decompose at and below operating temperature or about 200° C.
558. The cartridge of any one of embodiments 523-557, wherein the acid does not oxidize at and below operating temperature or about 200° C.
559. The cartridge of any one of embodiments 523-558, wherein the formulation is non-corrosive to the electronic cigarette.
560. The cartridge of any one of embodiments 523-559, wherein the formulation is non-toxic to a user of the electronic cigarette.
561. The cartridge of any one of embodiments 523-560, wherein the formulation further comprises one or more additional nicotine salts in a biologically acceptable liquid carrier suitable for generating the inhalable aerosol upon heating.
562. The cartridge of embodiment 561, wherein a second acid used to form the additional nicotine salt is selected from the group consisting of salicylic acid, sorbic acid, benzoic acid, pyruvic acid, lauric acid, and levulinic acid.
Although preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein can be employed in practicing the invention. It is intended that the following embodiments define the scope of the invention and that methods and structures within the scope of these embodiments and their equivalents be covered thereby.
This application is a continuation of U.S. patent application Ser. No. 14/271,071, filed May 6, 2014, titled “NICOTINE SALT FORMULATIONS FOR AEROSOL DEVICES AND METHODS THEREOF,” now U.S. Patent Publication No. 2014-0345631-A1, which claims the benefit of U.S. Provisional Patent Application No. 61/820,128, filed May 6, 2013, and U.S. Provisional Patent Application No. 61/912,507, filed Dec. 5, 2013, which are incorporated herein by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 374584 | Cook | Dec 1887 | A |
| 576653 | Bowlby | Feb 1897 | A |
| 595070 | Oldenbusch | Dec 1897 | A |
| 720007 | Dexter | Feb 1903 | A |
| 799844 | Fuller | Sep 1905 | A |
| 968160 | Johnson | Aug 1910 | A |
| 969076 | Pender | Aug 1910 | A |
| 1067531 | MacGregor | Jul 1913 | A |
| 1163183 | Stoll | Dec 1915 | A |
| 1299162 | Fisher | Apr 1919 | A |
| 1505748 | Louis | Aug 1924 | A |
| 1552877 | Phillipps et al. | Sep 1925 | A |
| 1632335 | Hiering | Jun 1927 | A |
| 1706244 | Louis | Mar 1929 | A |
| 1845340 | Ritz | Feb 1932 | A |
| 1972118 | McDill | Sep 1934 | A |
| 1998683 | Montgomery | Apr 1935 | A |
| 2031363 | Elof | Feb 1936 | A |
| 2039559 | Segal | May 1936 | A |
| 2104266 | McCormick | Jan 1938 | A |
| 2159698 | Harris et al. | May 1939 | A |
| 2177636 | Coffelt et al. | Oct 1939 | A |
| 2195260 | Rasener | Mar 1940 | A |
| 2231909 | Hempel | Feb 1941 | A |
| 2327120 | McCoon | Aug 1943 | A |
| 2460427 | Musselman et al. | Feb 1949 | A |
| 2483304 | Rudolf | Sep 1949 | A |
| 2502561 | Ludwig | Apr 1950 | A |
| 2765949 | Swan | Oct 1956 | A |
| 2830597 | Jakob | Apr 1958 | A |
| 2860638 | Frank | Nov 1958 | A |
| 2897958 | Tarleton et al. | Aug 1959 | A |
| 2935987 | Ackerbauer | May 1960 | A |
| 3146937 | Joseph | Sep 1964 | A |
| 3258015 | Ellis et al. | Jun 1966 | A |
| 3271719 | Ovshinsky | Sep 1966 | A |
| 3292634 | Beucler | Dec 1966 | A |
| 3373915 | Anderson et al. | Mar 1968 | A |
| 3420360 | Young | Jan 1969 | A |
| 3443827 | Acker et al. | May 1969 | A |
| 3456645 | Brock | Jul 1969 | A |
| 3479561 | Janning | Nov 1969 | A |
| 3567014 | Feigelman | Mar 1971 | A |
| 3675661 | Weaver | Jul 1972 | A |
| 3707017 | Paquette | Dec 1972 | A |
| 3792704 | Parker | Feb 1974 | A |
| 3815597 | Goettelman | Jun 1974 | A |
| 3861523 | Fountain et al. | Jan 1975 | A |
| 3941300 | Troth | Mar 1976 | A |
| 4020853 | Nuttall | May 1977 | A |
| 4049005 | Hernandez et al. | Sep 1977 | A |
| 4066088 | Ensor | Jan 1978 | A |
| 4207976 | Herman | Jun 1980 | A |
| 4215708 | Bron | Aug 1980 | A |
| 4219032 | Tabatznik et al. | Aug 1980 | A |
| 4303083 | Burruss, Jr. | Dec 1981 | A |
| 4312367 | Seeman | Jan 1982 | A |
| 4506683 | Cantrell et al. | Mar 1985 | A |
| 4519319 | Howlett | May 1985 | A |
| 4520938 | Finke | Jun 1985 | A |
| 4579858 | Ferno et al. | Apr 1986 | A |
| 4595024 | Greene et al. | Jun 1986 | A |
| 4597961 | Etscorn | Jul 1986 | A |
| 4648393 | Landis et al. | Mar 1987 | A |
| 4708151 | Shelar | Nov 1987 | A |
| 4735217 | Gerth et al. | Apr 1988 | A |
| 4771796 | Myer | Sep 1988 | A |
| 4793365 | Sensabaugh, Jr. et al. | Dec 1988 | A |
| 4794323 | Zhou et al. | Dec 1988 | A |
| 4798310 | Kasai et al. | Jan 1989 | A |
| 4813536 | Willis | Mar 1989 | A |
| 4819665 | Roberts et al. | Apr 1989 | A |
| 4830028 | Lawson et al. | May 1989 | A |
| 4836224 | Lawson et al. | Jun 1989 | A |
| 4846199 | Rose | Jul 1989 | A |
| 4848374 | Chard et al. | Jul 1989 | A |
| 4848563 | Robbins | Jul 1989 | A |
| 4893639 | White | Jan 1990 | A |
| 4907606 | Lilja et al. | Mar 1990 | A |
| 4941483 | Ridings et al. | Jul 1990 | A |
| 4944317 | Thal | Jul 1990 | A |
| 4947874 | Brooks et al. | Aug 1990 | A |
| 4947875 | Brooks et al. | Aug 1990 | A |
| 5005759 | Bouche | Apr 1991 | A |
| 5020548 | Farrier et al. | Jun 1991 | A |
| 5027836 | Shannon et al. | Jul 1991 | A |
| 5031646 | Lippiello et al. | Jul 1991 | A |
| 5042509 | Banerjee et al. | Aug 1991 | A |
| 5050621 | Creighton et al. | Sep 1991 | A |
| 5060671 | Counts et al. | Oct 1991 | A |
| 5065776 | Lawson et al. | Nov 1991 | A |
| 5076297 | Farrier et al. | Dec 1991 | A |
| 5105831 | Banerjee et al. | Apr 1992 | A |
| 5105838 | White et al. | Apr 1992 | A |
| 5123530 | Lee | Jun 1992 | A |
| 5133368 | Neumann et al. | Jul 1992 | A |
| 5141004 | Porenski | Aug 1992 | A |
| 5144962 | Counts et al. | Sep 1992 | A |
| 5152456 | Ross et al. | Oct 1992 | A |
| 5183062 | Clearman et al. | Feb 1993 | A |
| 5224498 | Deevi et al. | Jul 1993 | A |
| 5240012 | Ehrman et al. | Aug 1993 | A |
| 5249586 | Morgan et al. | Oct 1993 | A |
| 5261424 | Sprinkel, Jr. | Nov 1993 | A |
| 5269237 | Baker et al. | Dec 1993 | A |
| 5269327 | Counts et al. | Dec 1993 | A |
| 5303720 | Banerjee et al. | Apr 1994 | A |
| 5322075 | Deevi et al. | Jun 1994 | A |
| 5324498 | Streusand et al. | Jun 1994 | A |
| 5372148 | McCafferty et al. | Dec 1994 | A |
| 5388574 | Ingebrethsen | Feb 1995 | A |
| 5449078 | Akers | Sep 1995 | A |
| 5456269 | Kollasch | Oct 1995 | A |
| 5497791 | Bowen et al. | Mar 1996 | A |
| 5529078 | Rehder et al. | Jun 1996 | A |
| 5579934 | Buono et al. | Dec 1996 | A |
| 5591368 | Fleischhauer et al. | Jan 1997 | A |
| 5605226 | Hernlein | Feb 1997 | A |
| 5626866 | Ebert et al. | May 1997 | A |
| 5641064 | Goserud | Jun 1997 | A |
| 5649552 | Cho et al. | Jul 1997 | A |
| 5666977 | Higgins et al. | Sep 1997 | A |
| 5666978 | Counts et al. | Sep 1997 | A |
| 5708258 | Counts et al. | Jan 1998 | A |
| 5730118 | Hermanson | Mar 1998 | A |
| 5730158 | Collins et al. | Mar 1998 | A |
| 5746587 | Racine et al. | May 1998 | A |
| 5810164 | Rennecamp | Sep 1998 | A |
| 5819756 | Mielordt | Oct 1998 | A |
| 5845649 | Saito et al. | Dec 1998 | A |
| 5865185 | Collins et al. | Feb 1999 | A |
| 5878752 | Adams et al. | Mar 1999 | A |
| 5881884 | Podosek | Mar 1999 | A |
| 5894841 | Voges | Apr 1999 | A |
| 5931828 | Durkee | Aug 1999 | A |
| 5934289 | Watkins et al. | Aug 1999 | A |
| 5938018 | Keaveney et al. | Aug 1999 | A |
| 5944025 | Cook et al. | Aug 1999 | A |
| 5954979 | Counts et al. | Sep 1999 | A |
| 5967310 | Hill | Oct 1999 | A |
| 5975415 | Zehnal | Nov 1999 | A |
| 5979460 | Matsumura | Nov 1999 | A |
| 5994025 | Iwasa et al. | Nov 1999 | A |
| 5996589 | St. Charles | Dec 1999 | A |
| 6053176 | Adams et al. | Apr 2000 | A |
| 6089857 | Matsuura et al. | Jul 2000 | A |
| 6095153 | Kessler et al. | Aug 2000 | A |
| 6102036 | Slutsky et al. | Aug 2000 | A |
| 6125853 | Susa et al. | Oct 2000 | A |
| 6155268 | Takeuchi | Dec 2000 | A |
| 6164287 | White | Dec 2000 | A |
| 6196232 | Chkadua | Mar 2001 | B1 |
| 6211194 | Westman et al. | Apr 2001 | B1 |
| 6234169 | Bulbrook et al. | May 2001 | B1 |
| 6269966 | Pallo et al. | Aug 2001 | B1 |
| 6324261 | Merte | Nov 2001 | B1 |
| 6344222 | Cherukuri et al. | Feb 2002 | B1 |
| 6349728 | Pham | Feb 2002 | B1 |
| 6381739 | Breternitz, Jr. et al. | Apr 2002 | B1 |
| 6386371 | Parsons | May 2002 | B1 |
| 6431363 | Hacker | Aug 2002 | B1 |
| 6446793 | Layshock | Sep 2002 | B1 |
| 6510982 | White et al. | Jan 2003 | B2 |
| 6532965 | Abhulimen et al. | Mar 2003 | B1 |
| 6536442 | St. Charles et al. | Mar 2003 | B2 |
| 6557708 | Polacco | May 2003 | B2 |
| 6598607 | Adiga et al. | Jul 2003 | B2 |
| 6603924 | Brown et al. | Aug 2003 | B2 |
| 6606998 | Gold | Aug 2003 | B1 |
| 6612404 | Sweet et al. | Sep 2003 | B2 |
| 6615840 | Fournier et al. | Sep 2003 | B1 |
| 6622867 | Menceles | Sep 2003 | B2 |
| 6655379 | Clark et al. | Dec 2003 | B2 |
| 6672762 | Faircloth et al. | Jan 2004 | B1 |
| 6688313 | Wrenn et al. | Feb 2004 | B2 |
| 6726006 | Funderburk et al. | Apr 2004 | B1 |
| 6772756 | Shayan | Aug 2004 | B2 |
| 6799576 | Farr | Oct 2004 | B2 |
| 6803545 | Blake et al. | Oct 2004 | B2 |
| 6805545 | Slaboden | Oct 2004 | B2 |
| 6810883 | Felter et al. | Nov 2004 | B2 |
| 6827573 | St. Charles et al. | Dec 2004 | B2 |
| 6874507 | Farr | Apr 2005 | B2 |
| 6909840 | Harwig et al. | Jun 2005 | B2 |
| 6954979 | Logan | Oct 2005 | B2 |
| 7000775 | Gelardi et al. | Feb 2006 | B2 |
| 7015796 | Snyder | Mar 2006 | B2 |
| 7025066 | Lawson et al. | Apr 2006 | B2 |
| 7374048 | Mazurek | May 2008 | B2 |
| 7428905 | Mua | Sep 2008 | B2 |
| 7488171 | St. Charles et al. | Feb 2009 | B2 |
| D590990 | Hon | Apr 2009 | S |
| D590991 | Hon | Apr 2009 | S |
| 7546703 | Johnske et al. | Jun 2009 | B2 |
| 7621403 | Althoff et al. | Nov 2009 | B2 |
| 7644823 | Gelardi et al. | Jan 2010 | B2 |
| 7726320 | Robinson et al. | Jun 2010 | B2 |
| 7766013 | Wensley et al. | Aug 2010 | B2 |
| 7767698 | Warchol et al. | Aug 2010 | B2 |
| D624238 | Turner | Sep 2010 | S |
| 7801573 | Yazdi et al. | Sep 2010 | B2 |
| 7815332 | Smith | Oct 2010 | B1 |
| 7832410 | Hon | Nov 2010 | B2 |
| 7886507 | McGuinness, Jr. | Feb 2011 | B2 |
| D642330 | Turner | Jul 2011 | S |
| D644375 | Zhou | Aug 2011 | S |
| 7988034 | Pezzoli | Aug 2011 | B2 |
| 8003080 | Rabinowitz et al. | Aug 2011 | B2 |
| 8079371 | Robinson et al. | Dec 2011 | B2 |
| D653803 | Timmermans | Feb 2012 | S |
| 8141701 | Hodges | Mar 2012 | B2 |
| 8156944 | Hon | Apr 2012 | B2 |
| 8251060 | White et al. | Aug 2012 | B2 |
| 8308624 | Travers et al. | Nov 2012 | B2 |
| 8314235 | Dixit et al. | Nov 2012 | B2 |
| 8322350 | Lipowicz | Dec 2012 | B2 |
| 8371310 | Brenneise | Feb 2013 | B2 |
| 8375957 | Hon | Feb 2013 | B2 |
| 8381739 | Gonda | Feb 2013 | B2 |
| 8387612 | Damani et al. | Mar 2013 | B2 |
| 8443534 | Goodfellow et al. | May 2013 | B2 |
| 8464867 | Holloway et al. | Jun 2013 | B2 |
| 8479747 | O'Connell | Jul 2013 | B2 |
| 8490629 | Shenassa et al. | Jul 2013 | B1 |
| 8511318 | Hon | Aug 2013 | B2 |
| 8539959 | Scatterday | Sep 2013 | B1 |
| 8541401 | Mishra et al. | Sep 2013 | B2 |
| D691324 | Saliman | Oct 2013 | S |
| 8550069 | Alelov | Oct 2013 | B2 |
| D695450 | Benassayag et al. | Dec 2013 | S |
| 8596460 | Scatterday | Dec 2013 | B2 |
| 8671952 | Winterson et al. | Mar 2014 | B2 |
| 8707965 | Newton | Apr 2014 | B2 |
| 8714150 | Alelov | May 2014 | B2 |
| D707389 | Liu | Jun 2014 | S |
| 8741348 | Hansson et al. | Jun 2014 | B2 |
| 8794245 | Scatterday | Aug 2014 | B1 |
| 8794434 | Scatterday et al. | Aug 2014 | B2 |
| 8809261 | Elsohly et al. | Aug 2014 | B2 |
| 8820330 | Bellinger et al. | Sep 2014 | B2 |
| 8851081 | Fernando et al. | Oct 2014 | B2 |
| 8851083 | Oglesby et al. | Oct 2014 | B2 |
| 8881737 | Collett et al. | Nov 2014 | B2 |
| 8899238 | Robinson et al. | Dec 2014 | B2 |
| 8905040 | Scatterday et al. | Dec 2014 | B2 |
| 8910641 | Hon | Dec 2014 | B2 |
| 8915254 | Monsees et al. | Dec 2014 | B2 |
| 8919561 | Boisseau | Dec 2014 | B2 |
| 8925555 | Monsees et al. | Jan 2015 | B2 |
| 8931492 | Scatterday | Jan 2015 | B2 |
| D725310 | Eksouzian | Mar 2015 | S |
| 8991402 | Bowen et al. | Mar 2015 | B2 |
| 9004073 | Tucker et al. | Apr 2015 | B2 |
| 9072321 | Liu | Jul 2015 | B2 |
| 9095175 | Terry et al. | Aug 2015 | B2 |
| 9215895 | Bowen | Dec 2015 | B2 |
| 9220302 | DePiano et al. | Dec 2015 | B2 |
| 9226526 | Liu | Jan 2016 | B2 |
| 9254002 | Chong et al. | Feb 2016 | B2 |
| 9255277 | Bakker et al. | Feb 2016 | B2 |
| 9271525 | Liu | Mar 2016 | B2 |
| 9271529 | Alima | Mar 2016 | B2 |
| 9272103 | Storz | Mar 2016 | B2 |
| 9277768 | Xiu | Mar 2016 | B2 |
| 9277769 | Liu | Mar 2016 | B2 |
| 9282772 | Tucker et al. | Mar 2016 | B2 |
| 9282773 | Greim et al. | Mar 2016 | B2 |
| 9289014 | Tucker et al. | Mar 2016 | B2 |
| 9308336 | Newton | Apr 2016 | B2 |
| 9315890 | Frick et al. | Apr 2016 | B1 |
| 9319865 | Van Phan et al. | Apr 2016 | B2 |
| 9326547 | Tucker et al. | May 2016 | B2 |
| 9345269 | Liu | May 2016 | B2 |
| 9351522 | Safari | May 2016 | B2 |
| 9380810 | Rose et al. | Jul 2016 | B2 |
| 9420829 | Thorens et al. | Aug 2016 | B2 |
| 9427022 | Levin et al. | Aug 2016 | B2 |
| 9456632 | Hon | Oct 2016 | B2 |
| 9462832 | Lord | Oct 2016 | B2 |
| 9497995 | Liu | Nov 2016 | B2 |
| 9510624 | Li et al. | Dec 2016 | B2 |
| 9538781 | Zheng | Jan 2017 | B2 |
| 9554597 | Liu | Jan 2017 | B2 |
| 9596881 | Chiolini et al. | Mar 2017 | B2 |
| 9629391 | Dube et al. | Apr 2017 | B2 |
| 9635886 | Tu | May 2017 | B2 |
| 9642397 | Dai et al. | May 2017 | B2 |
| 9648905 | Levitz et al. | May 2017 | B2 |
| 9675108 | Liu | Jun 2017 | B2 |
| 9682203 | Dahne et al. | Jun 2017 | B2 |
| 9682204 | Matsumoto et al. | Jun 2017 | B2 |
| 9687025 | Cyphert et al. | Jun 2017 | B2 |
| 9687027 | Poston et al. | Jun 2017 | B2 |
| 9693584 | Hearn et al. | Jul 2017 | B2 |
| 9717274 | Daehne et al. | Aug 2017 | B2 |
| 9717279 | Hon | Aug 2017 | B2 |
| 20010015209 | Zielke | Aug 2001 | A1 |
| 20010032643 | Hochrainer et al. | Oct 2001 | A1 |
| 20010032795 | Weinstein et al. | Oct 2001 | A1 |
| 20010052480 | Kawaguchi et al. | Dec 2001 | A1 |
| 20020043554 | White et al. | Apr 2002 | A1 |
| 20020059939 | Fox | May 2002 | A1 |
| 20020078951 | Nichols et al. | Jun 2002 | A1 |
| 20020175164 | Dees et al. | Nov 2002 | A1 |
| 20030005926 | Jones et al. | Jan 2003 | A1 |
| 20030089377 | Hajaligol et al. | May 2003 | A1 |
| 20040002520 | Soderlund et al. | Jan 2004 | A1 |
| 20040031495 | Steinberg | Feb 2004 | A1 |
| 20040050382 | Goodchild | Mar 2004 | A1 |
| 20040099266 | Cross et al. | May 2004 | A1 |
| 20040149296 | Rostami et al. | Aug 2004 | A1 |
| 20040149624 | Wischusen et al. | Aug 2004 | A1 |
| 20040173229 | Crooks et al. | Sep 2004 | A1 |
| 20040182403 | Andersson et al. | Sep 2004 | A1 |
| 20040191322 | Hansson | Sep 2004 | A1 |
| 20040221857 | Dominguez | Nov 2004 | A1 |
| 20040237974 | Min | Dec 2004 | A1 |
| 20050016549 | Banerjee et al. | Jan 2005 | A1 |
| 20050016550 | Katase | Jan 2005 | A1 |
| 20050034723 | Bennett et al. | Feb 2005 | A1 |
| 20050061759 | Doucette | Mar 2005 | A1 |
| 20050118545 | Wong | Jun 2005 | A1 |
| 20050145533 | Seligson | Jul 2005 | A1 |
| 20050169849 | Farr | Aug 2005 | A1 |
| 20050172976 | Newman et al. | Aug 2005 | A1 |
| 20050244521 | Strickland et al. | Nov 2005 | A1 |
| 20050268911 | Cross et al. | Dec 2005 | A1 |
| 20060018840 | Lechuga Ballesteros et al. | Jan 2006 | A1 |
| 20060054676 | Wischusen | Mar 2006 | A1 |
| 20060102175 | Nelson | May 2006 | A1 |
| 20060150991 | Lee | Jul 2006 | A1 |
| 20060157072 | Albino et al. | Jul 2006 | A1 |
| 20060191546 | Takano et al. | Aug 2006 | A1 |
| 20060191548 | Strickland et al. | Aug 2006 | A1 |
| 20060196518 | Hon | Sep 2006 | A1 |
| 20060254948 | Herbert et al. | Nov 2006 | A1 |
| 20060255105 | Sweet | Nov 2006 | A1 |
| 20070006889 | Kobal et al. | Jan 2007 | A1 |
| 20070045288 | Nelson | Mar 2007 | A1 |
| 20070062548 | Horstmann et al. | Mar 2007 | A1 |
| 20070074734 | Braunshteyn et al. | Apr 2007 | A1 |
| 20070098148 | Sherman | May 2007 | A1 |
| 20070102013 | Adams et al. | May 2007 | A1 |
| 20070144514 | Yeates et al. | Jun 2007 | A1 |
| 20070163610 | Lindell et al. | Jul 2007 | A1 |
| 20070215164 | Mehio | Sep 2007 | A1 |
| 20070235046 | Gedevanishvili | Oct 2007 | A1 |
| 20070267031 | Hon | Nov 2007 | A1 |
| 20070267033 | Mishra et al. | Nov 2007 | A1 |
| 20070277816 | Morrison et al. | Dec 2007 | A1 |
| 20070280652 | Williams | Dec 2007 | A1 |
| 20070283972 | Monsees et al. | Dec 2007 | A1 |
| 20080000763 | Cove | Jan 2008 | A1 |
| 20080023003 | Rosenthal | Jan 2008 | A1 |
| 20080029095 | Esser | Feb 2008 | A1 |
| 20080092912 | Robinson et al. | Apr 2008 | A1 |
| 20080149118 | Oglesby et al. | Jun 2008 | A1 |
| 20080216828 | Wensley et al. | Sep 2008 | A1 |
| 20080228214 | Hoan et al. | Sep 2008 | A1 |
| 20080241255 | Rose et al. | Oct 2008 | A1 |
| 20080257367 | Paterno et al. | Oct 2008 | A1 |
| 20080276947 | Martzel | Nov 2008 | A1 |
| 20080286340 | Andersson et al. | Nov 2008 | A1 |
| 20080302375 | Andersson et al. | Dec 2008 | A1 |
| 20090004249 | Gonda | Jan 2009 | A1 |
| 20090095287 | Emarlou | Apr 2009 | A1 |
| 20090095311 | Han | Apr 2009 | A1 |
| 20090111287 | Lindberg et al. | Apr 2009 | A1 |
| 20090126745 | Hon | May 2009 | A1 |
| 20090133691 | Yamada et al. | May 2009 | A1 |
| 20090151717 | Bowen | Jun 2009 | A1 |
| 20090230117 | Fernando et al. | Sep 2009 | A1 |
| 20090255534 | Paterno | Oct 2009 | A1 |
| 20090267252 | Ikeyama | Oct 2009 | A1 |
| 20090272379 | Thorens et al. | Nov 2009 | A1 |
| 20090283103 | Nielsen et al. | Nov 2009 | A1 |
| 20090288668 | Inagaki | Nov 2009 | A1 |
| 20090288669 | Hutchens | Nov 2009 | A1 |
| 20090293892 | Williams et al. | Dec 2009 | A1 |
| 20090293895 | Axelsson et al. | Dec 2009 | A1 |
| 20100000672 | Fogle | Jan 2010 | A1 |
| 20100006092 | Hale et al. | Jan 2010 | A1 |
| 20100024834 | Oglesby et al. | Feb 2010 | A1 |
| 20100031968 | Sheikh et al. | Feb 2010 | A1 |
| 20100156193 | Rhodes et al. | Jun 2010 | A1 |
| 20100163063 | Fernando et al. | Jul 2010 | A1 |
| 20100186757 | Crooks et al. | Jul 2010 | A1 |
| 20100200006 | Robinson et al. | Aug 2010 | A1 |
| 20100200008 | Taieb | Aug 2010 | A1 |
| 20100236562 | Hearn et al. | Sep 2010 | A1 |
| 20100242974 | Pan | Sep 2010 | A1 |
| 20100242976 | Katayama et al. | Sep 2010 | A1 |
| 20100275938 | Roth et al. | Nov 2010 | A1 |
| 20100276333 | Couture | Nov 2010 | A1 |
| 20100307116 | Fisher | Dec 2010 | A1 |
| 20110030706 | Gibson et al. | Feb 2011 | A1 |
| 20110036346 | Cohen et al. | Feb 2011 | A1 |
| 20110041861 | Sebastian et al. | Feb 2011 | A1 |
| 20110049226 | Moreau et al. | Mar 2011 | A1 |
| 20110094523 | Thorens et al. | Apr 2011 | A1 |
| 20110108023 | McKinney et al. | May 2011 | A1 |
| 20110155153 | Thorens et al. | Jun 2011 | A1 |
| 20110162667 | Burke et al. | Jul 2011 | A1 |
| 20110168194 | Hon | Jul 2011 | A1 |
| 20110180433 | Rennecamp | Jul 2011 | A1 |
| 20110192397 | Saskar et al. | Aug 2011 | A1 |
| 20110226236 | Buchberger | Sep 2011 | A1 |
| 20110226266 | Tao | Sep 2011 | A1 |
| 20110232654 | Mass | Sep 2011 | A1 |
| 20110236002 | Oglesby et al. | Sep 2011 | A1 |
| 20110240047 | Adamic | Oct 2011 | A1 |
| 20110265806 | Alarcon et al. | Nov 2011 | A1 |
| 20110268809 | Brinkley et al. | Nov 2011 | A1 |
| 20110274628 | Borschke | Nov 2011 | A1 |
| 20110277780 | Terry et al. | Nov 2011 | A1 |
| 20110278189 | Terry et al. | Nov 2011 | A1 |
| 20110293535 | Kosik et al. | Dec 2011 | A1 |
| 20110315701 | Everson | Dec 2011 | A1 |
| 20120006342 | Rose et al. | Jan 2012 | A1 |
| 20120039981 | Pedersen et al. | Feb 2012 | A1 |
| 20120060853 | Robinson et al. | Mar 2012 | A1 |
| 20120111347 | Hon | May 2012 | A1 |
| 20120152265 | Dube et al. | Jun 2012 | A1 |
| 20120192880 | Dube et al. | Aug 2012 | A1 |
| 20120199146 | Marangos | Aug 2012 | A1 |
| 20120204889 | Xiu | Aug 2012 | A1 |
| 20120227753 | Newton | Sep 2012 | A1 |
| 20120255567 | Rose et al. | Oct 2012 | A1 |
| 20120260927 | Liu | Oct 2012 | A1 |
| 20120261286 | Holloway et al. | Oct 2012 | A1 |
| 20120267383 | Van Rooyen | Oct 2012 | A1 |
| 20120273589 | Hon | Nov 2012 | A1 |
| 20120285475 | Liu | Nov 2012 | A1 |
| 20120325227 | Robinson et al. | Dec 2012 | A1 |
| 20130042865 | Monsees et al. | Feb 2013 | A1 |
| 20130068239 | Youn | Mar 2013 | A1 |
| 20130081642 | Safari | Apr 2013 | A1 |
| 20130098377 | Borschke et al. | Apr 2013 | A1 |
| 20130140200 | Scatterday | Jun 2013 | A1 |
| 20130152922 | Benassayag et al. | Jun 2013 | A1 |
| 20130186416 | Gao et al. | Jul 2013 | A1 |
| 20130199528 | Goodman et al. | Aug 2013 | A1 |
| 20130228191 | Newton | Sep 2013 | A1 |
| 20130247924 | Scatterday et al. | Sep 2013 | A1 |
| 20130248385 | Scatterday et al. | Sep 2013 | A1 |
| 20130255702 | Griffith, Jr. et al. | Oct 2013 | A1 |
| 20130276802 | Scatterday | Oct 2013 | A1 |
| 20130284190 | Scatterday et al. | Oct 2013 | A1 |
| 20130284191 | Scatterday et al. | Oct 2013 | A1 |
| 20130298905 | Levin et al. | Nov 2013 | A1 |
| 20130312742 | Monsees et al. | Nov 2013 | A1 |
| 20130313139 | Scatterday et al. | Nov 2013 | A1 |
| 20130319435 | Flick | Dec 2013 | A1 |
| 20130319440 | Capuano | Dec 2013 | A1 |
| 20130333700 | Buchberger | Dec 2013 | A1 |
| 20130333712 | Scatterday | Dec 2013 | A1 |
| 20130340775 | Juster et al. | Dec 2013 | A1 |
| 20140000638 | Sebastian et al. | Jan 2014 | A1 |
| 20140007891 | Liu | Jan 2014 | A1 |
| 20140014124 | Glasberg et al. | Jan 2014 | A1 |
| 20140014126 | Peleg et al. | Jan 2014 | A1 |
| 20140041655 | Barron et al. | Feb 2014 | A1 |
| 20140041658 | Goodman et al. | Feb 2014 | A1 |
| 20140053856 | Liu | Feb 2014 | A1 |
| 20140053858 | Liu | Feb 2014 | A1 |
| 20140060552 | Cohen | Mar 2014 | A1 |
| 20140060556 | Liu | Mar 2014 | A1 |
| 20140096781 | Sears et al. | Apr 2014 | A1 |
| 20140096782 | Ampolini et al. | Apr 2014 | A1 |
| 20140109921 | Chen | Apr 2014 | A1 |
| 20140116455 | Youn | May 2014 | A1 |
| 20140123990 | Timmermans | May 2014 | A1 |
| 20140144429 | Wensley et al. | May 2014 | A1 |
| 20140150810 | Hon | Jun 2014 | A1 |
| 20140166028 | Fuisz et al. | Jun 2014 | A1 |
| 20140174459 | Burstyn | Jun 2014 | A1 |
| 20140190501 | Liu | Jul 2014 | A1 |
| 20140190503 | Li et al. | Jul 2014 | A1 |
| 20140196731 | Scatterday | Jul 2014 | A1 |
| 20140196735 | Liu | Jul 2014 | A1 |
| 20140202474 | Peleg et al. | Jul 2014 | A1 |
| 20140209105 | Sears et al. | Jul 2014 | A1 |
| 20140216450 | Liu | Aug 2014 | A1 |
| 20140230835 | Saliman | Aug 2014 | A1 |
| 20140261474 | Gonda | Sep 2014 | A1 |
| 20140261486 | Potter et al. | Sep 2014 | A1 |
| 20140261487 | Chapman et al. | Sep 2014 | A1 |
| 20140270727 | Ampolini et al. | Sep 2014 | A1 |
| 20140271946 | Kobal et al. | Sep 2014 | A1 |
| 20140301721 | Ruscio et al. | Oct 2014 | A1 |
| 20140305450 | Xiang | Oct 2014 | A1 |
| 20140345631 | Bowen et al. | Nov 2014 | A1 |
| 20140345633 | Talon et al. | Nov 2014 | A1 |
| 20140345635 | Rabinowitz et al. | Nov 2014 | A1 |
| 20140355969 | Stern | Dec 2014 | A1 |
| 20140366898 | Monsees et al. | Dec 2014 | A1 |
| 20140378790 | Cohen | Dec 2014 | A1 |
| 20150020823 | Lipowicz et al. | Jan 2015 | A1 |
| 20150020824 | Bowen et al. | Jan 2015 | A1 |
| 20150020825 | Galloway et al. | Jan 2015 | A1 |
| 20150020830 | Koller | Jan 2015 | A1 |
| 20150020831 | Weigensberg et al. | Jan 2015 | A1 |
| 20150027457 | Janardhan et al. | Jan 2015 | A1 |
| 20150027468 | Li et al. | Jan 2015 | A1 |
| 20150027472 | Amir | Jan 2015 | A1 |
| 20150034103 | Hon | Feb 2015 | A1 |
| 20150034104 | Zhou | Feb 2015 | A1 |
| 20150038567 | Herkenroth et al. | Feb 2015 | A1 |
| 20150040929 | Hon | Feb 2015 | A1 |
| 20150101625 | Newton et al. | Apr 2015 | A1 |
| 20150122252 | Frija | May 2015 | A1 |
| 20150122274 | Cohen et al. | May 2015 | A1 |
| 20150128965 | Lord | May 2015 | A1 |
| 20150128966 | Lord | May 2015 | A1 |
| 20150128967 | Robinson et al. | May 2015 | A1 |
| 20150128976 | Verleur et al. | May 2015 | A1 |
| 20150136153 | Lord | May 2015 | A1 |
| 20150136158 | Stevens et al. | May 2015 | A1 |
| 20150142387 | Alarcon et al. | May 2015 | A1 |
| 20150144147 | Li et al. | May 2015 | A1 |
| 20150150308 | Monsees et al. | Jun 2015 | A1 |
| 20150157054 | Liu | Jun 2015 | A1 |
| 20150157056 | Bowen et al. | Jun 2015 | A1 |
| 20150164141 | Newton | Jun 2015 | A1 |
| 20150164144 | Liu | Jun 2015 | A1 |
| 20150164147 | Verleur et al. | Jun 2015 | A1 |
| 20150181928 | Liu | Jul 2015 | A1 |
| 20150189695 | Xiang | Jul 2015 | A1 |
| 20150196059 | Liu | Jul 2015 | A1 |
| 20150196060 | Wensley et al. | Jul 2015 | A1 |
| 20150208729 | Monsees et al. | Jul 2015 | A1 |
| 20150208731 | Malamud et al. | Jul 2015 | A1 |
| 20150216237 | Wensley et al. | Aug 2015 | A1 |
| 20150223521 | Menting et al. | Aug 2015 | A1 |
| 20150224268 | Henry et al. | Aug 2015 | A1 |
| 20150237917 | Lord | Aug 2015 | A1 |
| 20150237918 | Liu | Aug 2015 | A1 |
| 20150245654 | Memari et al. | Sep 2015 | A1 |
| 20150245660 | Lord | Sep 2015 | A1 |
| 20150257445 | Henry, Jr. et al. | Sep 2015 | A1 |
| 20150258289 | Henry, Jr. et al. | Sep 2015 | A1 |
| 20150272220 | Spinka et al. | Oct 2015 | A1 |
| 20150272222 | Spinka et al. | Oct 2015 | A1 |
| 20150282525 | Plojoux et al. | Oct 2015 | A1 |
| 20150282527 | Henry, Jr. | Oct 2015 | A1 |
| 20150305409 | Verleur et al. | Oct 2015 | A1 |
| 20150313275 | Anderson et al. | Nov 2015 | A1 |
| 20150313285 | Waller et al. | Nov 2015 | A1 |
| 20150320114 | Wu | Nov 2015 | A1 |
| 20150335074 | Leung | Nov 2015 | A1 |
| 20150351456 | Johnson et al. | Dec 2015 | A1 |
| 20150359264 | Fernando et al. | Dec 2015 | A1 |
| 20150366265 | Lansing | Dec 2015 | A1 |
| 20150366266 | Chen | Dec 2015 | A1 |
| 20160021931 | Hawes et al. | Jan 2016 | A1 |
| 20160021932 | Silvestrini et al. | Jan 2016 | A1 |
| 20160021933 | Thorens et al. | Jan 2016 | A1 |
| 20160021934 | Cadieux et al. | Jan 2016 | A1 |
| 20160029694 | Malgat et al. | Feb 2016 | A1 |
| 20160029697 | Shafer | Feb 2016 | A1 |
| 20160029698 | Xiang | Feb 2016 | A1 |
| 20160044967 | Bowen et al. | Feb 2016 | A1 |
| 20160044968 | Bowen et al. | Feb 2016 | A1 |
| 20160053988 | Quintana | Feb 2016 | A1 |
| 20160057811 | Alarcon et al. | Feb 2016 | A1 |
| 20160058071 | Hearn | Mar 2016 | A1 |
| 20160058072 | Liu | Mar 2016 | A1 |
| 20160073692 | Alarcon et al. | Mar 2016 | A1 |
| 20160081393 | Black | Mar 2016 | A1 |
| 20160081395 | Thorens et al. | Mar 2016 | A1 |
| 20160095355 | Hearn | Apr 2016 | A1 |
| 20160106154 | Lord | Apr 2016 | A1 |
| 20160106155 | Reevell | Apr 2016 | A1 |
| 20160106936 | Kimmel | Apr 2016 | A1 |
| 20160109115 | Lipowicz | Apr 2016 | A1 |
| 20160120218 | Schennum et al. | May 2016 | A1 |
| 20160120220 | Malgat et al. | May 2016 | A1 |
| 20160120227 | Levitz et al. | May 2016 | A1 |
| 20160120228 | Rostami et al. | May 2016 | A1 |
| 20160135503 | Liu | May 2016 | A1 |
| 20160143359 | Xiang | May 2016 | A1 |
| 20160143365 | Liu | May 2016 | A1 |
| 20160157524 | Bowen et al. | Jun 2016 | A1 |
| 20160166564 | Myers et al. | Jun 2016 | A1 |
| 20160174611 | Monsees et al. | Jun 2016 | A1 |
| 20160200463 | Hodges et al. | Jul 2016 | A1 |
| 20160227839 | Zuber et al. | Aug 2016 | A1 |
| 20160227840 | Xiang et al. | Aug 2016 | A1 |
| 20160242466 | Lord et al. | Aug 2016 | A1 |
| 20160249680 | Liu | Sep 2016 | A1 |
| 20160250201 | Rose et al. | Sep 2016 | A1 |
| 20160270451 | Hon | Sep 2016 | A1 |
| 20160278435 | Choukroun et al. | Sep 2016 | A1 |
| 20160295924 | Liu | Oct 2016 | A1 |
| 20160295926 | Zuber | Oct 2016 | A1 |
| 20160302471 | Bowen et al. | Oct 2016 | A1 |
| 20160302483 | Liu | Oct 2016 | A1 |
| 20160302484 | Gupta et al. | Oct 2016 | A1 |
| 20160302486 | Eroch | Oct 2016 | A1 |
| 20160309784 | Silvestrini et al. | Oct 2016 | A1 |
| 20160324215 | Mironov et al. | Nov 2016 | A1 |
| 20160331033 | Hopps et al. | Nov 2016 | A1 |
| 20160331038 | Farine et al. | Nov 2016 | A1 |
| 20160331040 | Nakano et al. | Nov 2016 | A1 |
| 20160338402 | Buehler et al. | Nov 2016 | A1 |
| 20160338410 | Batista et al. | Nov 2016 | A1 |
| 20160338411 | Liu | Nov 2016 | A1 |
| 20160345627 | Liu et al. | Dec 2016 | A1 |
| 20160345630 | Mironov et al. | Dec 2016 | A1 |
| 20160366939 | Alarcon et al. | Dec 2016 | A1 |
| 20160368670 | Beardsall | Dec 2016 | A1 |
| 20160371464 | Bricker | Dec 2016 | A1 |
| 20160374390 | Liu | Dec 2016 | A1 |
| 20160374398 | Amir | Dec 2016 | A1 |
| 20170019951 | Louveau et al. | Jan 2017 | A1 |
| 20170049155 | Liu | Feb 2017 | A1 |
| 20170064999 | Perez et al. | Mar 2017 | A1 |
| 20170071257 | Lin | Mar 2017 | A1 |
| 20170079329 | Zitzke | Mar 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 2641869 | May 2010 | CA |
| 85106876 | Sep 1986 | CN |
| 1122213 | May 1996 | CN |
| 101869356 | Oct 2010 | CN |
| 102754924 | Oct 2012 | CN |
| 105263345 | Jan 2016 | CN |
| 4200639 | Jul 1992 | DE |
| 19854005 | May 2000 | DE |
| 19854012 | May 2000 | DE |
| 0532194 | Mar 1993 | EP |
| 0535695 | Apr 1993 | EP |
| 0283672 | Sep 1993 | EP |
| 1458388 | Sep 2004 | EP |
| 1618803 | Jan 2006 | EP |
| 2022349 | Feb 2009 | EP |
| 2022350 | Feb 2009 | EP |
| 2110033 | Oct 2009 | EP |
| 2325093 | Jun 2012 | EP |
| 2609821 | Jul 2013 | EP |
| 2152313 | Sep 2014 | EP |
| 3024343 | Jan 2015 | EP |
| 2856893 | Apr 2015 | EP |
| 2908675 | Aug 2015 | EP |
| 2319934 | Sep 2015 | EP |
| 2915443 | Sep 2015 | EP |
| 3062646 | Sep 2016 | EP |
| 3065581 | Sep 2016 | EP |
| 3068244 | Sep 2016 | EP |
| 2118034 | Sep 1998 | ES |
| 1025630 | Apr 1966 | GB |
| 1065678 | Apr 1967 | GB |
| S2005-0051 | Feb 2005 | IE |
| S2005-0563 | Aug 2005 | IE |
| S2005-0615 | Sep 2005 | IE |
| S61254170 | Nov 1986 | JP |
| 62-278975 | Dec 1987 | JP |
| 64-37276 | Feb 1989 | JP |
| 02-145179 | Jun 1990 | JP |
| 03-049671 | Mar 1991 | JP |
| 03-180166 | Aug 1991 | JP |
| 09-075058 | Mar 1997 | JP |
| 10-501999 | Feb 1998 | JP |
| 11-178563 | Jul 1999 | JP |
| 2000-203639 | Jul 2000 | JP |
| 2000-236865 | Sep 2000 | JP |
| 2001-165437 | Jun 2001 | JP |
| 2005-034021 | Feb 2005 | JP |
| 2006-504430 | Feb 2006 | JP |
| 2006524494 | Nov 2006 | JP |
| 0193885 | Jun 1999 | KR |
| 67598 | Feb 2012 | UA |
| WO9501137 | Jan 1995 | WO |
| WO9712639 | Apr 1997 | WO |
| WO0028842 | May 2000 | WO |
| WO-0028842 | May 2000 | WO |
| WO03056948 | Jul 2003 | WO |
| WO-03056948 | Jul 2003 | WO |
| WO03082031 | Oct 2003 | WO |
| WO03094900 | Nov 2003 | WO |
| WO 03103387 | Dec 2003 | WO |
| WO2004064548 | Aug 2004 | WO |
| 2004076289 | Sep 2004 | WO |
| WO2004080216 | Sep 2004 | WO |
| WO2005020726 | Mar 2005 | WO |
| WO-2006004646 | Jan 2006 | WO |
| WO2006015070 | Feb 2006 | WO |
| WO2007026131 | Mar 2007 | WO |
| WO2007078273 | Jul 2007 | WO |
| WO2008077271 | Jul 2008 | WO |
| 2008121610 | Oct 2008 | WO |
| 2009001085 | Dec 2008 | WO |
| 2009079641 | Jun 2009 | WO |
| WO2010023561 | Mar 2010 | WO |
| 2011034723 | Mar 2011 | WO |
| 2011038104 | Mar 2011 | WO |
| WO2011033396 | Mar 2011 | WO |
| WO2011117580 | Sep 2011 | WO |
| WO-2011109849 | Sep 2011 | WO |
| WO2012021972 | Feb 2012 | WO |
| WO2012027350 | Mar 2012 | WO |
| WO2012085207 | Jun 2012 | WO |
| WO2012120487 | Sep 2012 | WO |
| WO-2012120487 | Sep 2012 | WO |
| WO2013050934 | Apr 2013 | WO |
| WO-2013044537 | Apr 2013 | WO |
| 2013083631 | Jun 2013 | WO |
| 2013088230 | Jun 2013 | WO |
| WO2013083635 | Jun 2013 | WO |
| WO2013089551 | Jun 2013 | WO |
| WO2013098398 | Jul 2013 | WO |
| 2013116558 | Aug 2013 | WO |
| 2013116561 | Aug 2013 | WO |
| WO2013142678 | Sep 2013 | WO |
| 2014004648 | Jan 2014 | WO |
| WO2014040915 | Mar 2014 | WO |
| WO2014093127 | Jun 2014 | WO |
| WO2014101734 | Jul 2014 | WO |
| WO2014118286 | Aug 2014 | WO |
| 2014150245 | Sep 2014 | WO |
| 2014151434 | Sep 2014 | WO |
| WO2014139611 | Sep 2014 | WO |
| WO2014140087 | Sep 2014 | WO |
| WO2014150704 | Sep 2014 | WO |
| 2014159250 | Oct 2014 | WO |
| WO2014159982 | Oct 2014 | WO |
| 2014177859 | Nov 2014 | WO |
| 2014190079 | Nov 2014 | WO |
| WO2014187763 | Nov 2014 | WO |
| WO2014187770 | Nov 2014 | WO |
| WO-2014182736 | Nov 2014 | WO |
| WO2014205263 | Dec 2014 | WO |
| WO2015006652 | Jan 2015 | WO |
| WO2015009862 | Jan 2015 | WO |
| WO2015028815 | Mar 2015 | WO |
| WO2015040180 | Mar 2015 | WO |
| WO-2015042412 | Mar 2015 | WO |
| WO2015058387 | Apr 2015 | WO |
| WO2015063126 | May 2015 | WO |
| WO-2015066136 | May 2015 | WO |
| WO-2015073975 | May 2015 | WO |
| 2015091258 | Jun 2015 | WO |
| WO2015082652 | Jun 2015 | WO |
| WO2015084544 | Jun 2015 | WO |
| WO2015089711 | Jun 2015 | WO |
| WO2015101651 | Jul 2015 | WO |
| WO2015109616 | Jul 2015 | WO |
| WO2015124878 | Aug 2015 | WO |
| WO2015148547 | Oct 2015 | WO |
| WO2015149647 | Oct 2015 | WO |
| WO-2015157893 | Oct 2015 | WO |
| WO-2015157901 | Oct 2015 | WO |
| 2015179292 | Nov 2015 | WO |
| WO2015168828 | Nov 2015 | WO |
| WO2015175979 | Nov 2015 | WO |
| WO-2015165067 | Nov 2015 | WO |
| 2015193456 | Dec 2015 | WO |
| 2016012769 | Jan 2016 | WO |
| 2016020675 | Feb 2016 | WO |
| 2016030661 | Mar 2016 | WO |
| 2016040575 | Mar 2016 | WO |
| WO-2016041114 | Mar 2016 | WO |
| WO-2016041140 | Mar 2016 | WO |
| 2016062777 | Apr 2016 | WO |
| 2016063775 | Apr 2016 | WO |
| WO-2016050247 | Apr 2016 | WO |
| WO-2016058189 | Apr 2016 | WO |
| 2016071705 | May 2016 | WO |
| 2016071706 | May 2016 | WO |
| WO-2016065606 | May 2016 | WO |
| Entry |
|---|
| Baker et al.; The pyrolysis of tobacco ingredients; J. Anal. Appl. Pyrolysis; 71(1); pp. 223-311; Mar. 2004. |
| Bombick et al.; Chemcal and biological studies of a new cigarette that primarily heats tobacco; Part 3: In vitro toxicity of whole smoke; Food and Chemical Toxicology; 36(3); pp. 191-197; Mar. 1998. |
| Bombick et al.; Chemical and biological studies of a new cigarette that primarily heats tobacco; Part 2: In vitro toxicology of mainstream smoke condesnsate; Food and Chemical Toxicology; 36(3); pp. 183-190; Mar. 1998. |
| Borgerding et al.; Chemcal and biological studies of a new cigarette that primarily heats tobacco; Part 1: Chemical composition of mainstream smoke; Food and Chemical Toxicology; 36(3); pp. 169-182; Mar. 1998. |
| ECF; Any interest in determining nicotine—by DVAP; (https://www.e-cigarette-forum.com/forum/threads/any-interest-in-determining-nicotine-by-dvap.35922/); blog posts dated: 2009; 8 pgs.; print/retrieval date: Jul. 31, 2014. |
| Flouris et al.; Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function; Inhal. Toxicol.; 25(2); pp. 91-101; Feb. 2013. |
| Food & Drug Administration; Warning letter to the Compounding Pharmacy; retrieved Oct. 10, 2014 from http://www.fda.gov/ICECI/EnfocementActions/WarningLetters/2002/ucm144843.htm; 3 pgs.; Apr. 9, 2002. |
| Harvest Vapor; American Blend Tobacco (product info.); retrieved from the internet (http://harvestvapor.com/); 2 pgs.; print/retrieval date: Oct. 10, 2014. |
| Inchem; Benzoic Acid; JECFA Evaluation Summary; retrieved Oct. 10, 2014 from http://www.inchem.org/documents/jecfa/feceval/jec_184.htm; 2 pgs . . . ; May 28, 2005. |
| Inchem; Levulinic Acid; JECFA Evaluation Summary; retrieved Oct. 10, 2014 from http://www.inchem.org/documents/jecfa/feceval/jec_1266.htm; 1 pg.; Mar. 10, 2003. |
| Inchem; Pyruvic Acid; JECFA Evaluation Summary; retrieved Oct. 10, 2014 from http://www.inchem.org/documents/jecfa/feceval/jec_2072.htm; 1 pg.; Jan. 29, 2003. |
| Inchem; Sorbic Acid; JECFA Evaluation Summary; retrieved Oct. 10, 2014 from http://www.inchem.org/documents/jecfa/feceval/jec_2181.htm; 1 pg.; May 29, 2005. |
| Ingebrethsen et al.; Electronic cigarette aerosol particle size distribution measurements; Inhalation Toxicology; 24(14); pp. 976-984; Dec. 2012. |
| Kuo et al.; Appendix D: Particle size—U.S. sieve size and tyler screen mesh equivalents; Applications of Turbulent and Multiphase Combustion; John Wiley & Sons, Inc.; pp. 541-543; May 1, 2012. |
| McCann et al.; Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals: Discussion; Proc. Nat. Acad. Sci.; 73(3); pp. 950-954; Mar. 1976. |
| Mirriam-Webster Online Dictionary; Lighter; retrieved Jan. 4, 2013 from the internet: (http://www.merriam-webster.com/dictionary/lighter?show=0&t=1357320593); 2 pgs.; print date: Jan. 4, 2013. |
| Nicoli et al.; Mammalian tumor xenografts induce neovascularization in Zebrafish embryos; Cancer Research; 67(7); pp. 2927-2931; Apr. 1, 2007. |
| Torikai et al.; Effects of temperature, atmosphere and pH on the generation of smoke compounds duriung tobacco pyrolysis; Food and Chemical Toxicology; 42(9); pp. 1409-1417; Sep. 2004. |
| Vansickel et al.; A clinical laboratory model for evaluating the acute effects of electronic cigarettes: Nicotine delivery profile and cardiovascular and subjective effects; Cancer Epidemiology Biomarkers Prevention; 19(8); pp. 1945-1953; (online) Jul. 20, 2010. |
| Ward; Green leaf threshing and redrying tobacco; Section 10B; in Tobacco Production, Chemistry and Technology; Davis and Nielsen (Eds.); Blackwell Science Ltd.; pp. 330-333; Jul. 15, 1999. |
| Wells; Glycerin as a constituent of cosmetics and toilet preparations; Journal of the Society of Cosmetic Chemists; 9(1); pp. 19-25; Jan. 1958. |
| YouTube; Firefly Vaporizor Review w/ Usage Tips by the Vape Critic; retrieved from the internet (http://www.youtube.com/watch?v=1J38N0AV7wI); 1 pg.; published Dec. 10, 2013; download/print date: Feb. 18, 2015. |
| Zhang et al.; In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns; Nicotine Tobacco Research; 15(2); pp. 501-508; Feb. 2013. |
| Monsees, J.; U.S. Appl. No. 12/115,400 entitled “Method and System for Vaporization of a Substance”, filed May 5, 2008. |
| Bowen et al.; U.S. Appl. No. 14/960,259 entitled “Calibrated Dose Control”, filed Dec. 4, 2015. |
| E-Cigarette Forum; pg-gv-peg (discussion/posting); retrieved from the internet: https://e-cigarette-forum.com/forum/threads/pg-vg-peg.177551; 7 pgs.; Apr. 8, 2011. |
| Burch et al.; Effect of pH on nicotine absorption and side effects produced by aerosolized nicotine; Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung; 6(1); pp. 45-52; 1993. |
| Monsees et al.; U.S. Appl. No. 15/257,748 entitled “Cartridge for use with a vaporizer device,” filed Sep. 6, 2016. |
| Monsees et al.; U.S. Appl. No. 15/257,760 entitled “Vaporizer apparatus,” filed Sep. 6, 2016. |
| Monsees et al.; U.S. Appl. No. 15/257,768 entitled “Vaporizer apparatus,” filed Sep. 6, 2016. |
| Monsees et al.; U.S. Appl. No. 15/261,823 entitled “Low temperature , electronic vaporization device and methods,” filed Sep. 9, 2016. |
| Monsees et al.; U.S. Appl. No. 15/165,954 entitled “Devices for vaporization of a substance,” filed May 26, 2016. |
| Monsees et al.; U.S. Appl. No. 15/166,001 entitled “Electronic vaporization device,” filed May 26, 2016. |
| Monsees et al.; U.S. Appl. No. 15/165,972 entitled “Portable devices for generating an inhalable vapor,” filed May 26, 2016. |
| Bowen et al.; U.S. Appl. No. 15/101,303 entitled “Nicotine liquid formulations for aerosol devices and methods thereof,” filed Jun. 2, 2016. |
| Bradley et al.; Electronic cigarette aerosol particle size distribution measurements; Inhal. Toxicol.; 24(14); pp. 976-984; Dec. 2012. |
| Bullen et al.; Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial; Tobacco Control; 19(2); pp. 98-103; Apr. 2010. |
| Capponnetto et al.; Successful smoking cessation with cigarettes in smokers with a documented history of recurring relapses: a case series; Journal of Medical Case Reports; 5(1); 6 pages; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date); 2011. |
| Farsalinos et al.; Electronic cigarettes do not damage the heart; European Society of Cardiology; 4 pages; retrieved from the internet (http://www.escardio.org/The-ESC/Press-Office/Press-releases/Electronic-cigarettes-do-not-damage-the-heart); Aug. 25, 2012. |
| Hurt et al.; Treating tobacco dependence in a medical setting; CA: A Cancer Journal for Clinicians; 59(5); pp. 314-326; Sep. 2009. |
| Vansickel et al.; Electronic cigarettes: effective nicotine delivery after acute administration; Nicotine & Tobacco Research; 15(1); pp. 267-270; Jan. 2013. |
| “A Randomised Placebo-Controlled Trial of a Nicotine Inhaler and Nicotine Patches for Smoking cessation,” 5 pages, available at http://www.otago.ac.nz/wellington/otago047634.pdf. |
| “How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attibutable Disease,” U.S. Department of Health and Human Services, 2010. |
| Goniewicz, et al., “Nicotine levels in electronic cigarettes,” Nicotine Tobacco Research, 15(1), pp. 158-166, Jan. 2013. |
| Perfetti, “Structural study of nicotine salts,” Beitrage Zur Tabakforschung International, Contributions to Tobacco Research, 12(2), pp. 43-54. Jun. 1983. |
| Adam, Thomas, Stefan Mitschke, and Richard R. Baker. “Investigation of tobacco pyrolysis gases and puff-by-puff resolved cigarette smoke by single photon ionisation (SPI)—time-of-flight mass spectrometry (TOFMS).” Beiträge zur Tabakforschung International/Contributions to Tobacco Research 23.4 (2009): 203-226. |
| Baker, R., et al., “An overview of the effects of tobacco ingredients on smoke chemistry and toxicity,” Food and Chemical Toxicology, 42S, 2004. |
| Baker, R., et al., “The effect of tobacco ingredients on smoke chemisty. Part II: Casing ingredients,” Food and Chemical Toxicology, 42S, 2004. |
| Bao, M., et al., “An improved headspace solid-phase microextraction method for the analysis of free-base nicotine in particulate phase of mainstream cigarette smoke,” Analytica Chimic Acta, 49-54, 2010. |
| Bastin, R., et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Checmical Entities,” Organic Process Research & Development, 4, 427-435 (2000). |
| Bates, “Tobacco Additives: Cigarette Engineering and Nicotine Addiction,” ASH UK Report, 1999. |
| Bertholon, J. F., et al. “Comparison of the aerosol produced by electronic cigarettes with conventional cigarettes and the shisha.” Revue des maladies respiratoires 30.9 (2013): 752-757. |
| Bertholon, J. F., et al. “Electronic cigarettes: a short review.” Respiration 86.5 (2013): 433-438. |
| Brown, Christopher J., et al., “Electronic cigarettes: product characterisation and design considerations.” Tobacco control 23.suppl 2 (2014): ii4-ii10. |
| Brown, Christopher, et al., “Caffeine and Cigarette Smoking: Behavioral, Cardiovascular, and Metabolic Interactions,” Pharmacology Biochemistry and Behavior, vol. 34, pp. 565-570, 1989. |
| Bullen, Chris, et al. “Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation.” BMC public health 13.1 (2013): 210. |
| Bullen, Christopher, et al. “Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial.” Tobacco control 19.2 (2010): 98-103. |
| Burch, et al., “Effect of pH on nicotine absorption and side effects produced by areosolized nicotine,” Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung, 6(1), pp. 45-52. 1993. |
| Cahn, Zachary, et al., “Electronic cigarettes as a harm reduction strategy for tobacco control: a step forward or a repeat of past mistakes?.” Journal of public health policy 32.1 (2011): 16-31. |
| Caldwell, B., et al., “A Systematic Review of Nicotine by Inhalation: Is There a Role for the Inhaled Route?,” Nicotine & Tobacco Research, pp. 1-13 (2012). |
| Callicutt, C.H., “The role of ammonia in the transfer of nicotine from tobacco to mainstream smoke,” Regulatory Toxicology and Pharmacology, 46, 2006. |
| Caponnetto, Pasquale, et al. “EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study.” PloS one 8.6 (2013): e66317. |
| Caponnetto, Pasquale, et al. “The emerging phenomenon of electronic cigarettes.” Expert review of respiratory medicine 6.1 (2012): 63-74. |
| Cheng, Tianrong. “Chemical evaluation of electronic cigarettes.” Tobacco control 23.suppl 2 (2014): ii11-ii17. |
| Cig Buyer.com 2013 Inside E-Cigarette Liquids and Vapor. |
| Cisternino, S., et al., “Coexistence of Passive and Proton Anitporter-Mediated Processes in Nicotine Transport at the Mouse Blood-Brain Barrier,” The AAPS Journal, vol. 15, No. 2, Apr. 2013. |
| Dawkins, Lynne, et al. “The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition.” Addictive behaviors 37.8 (2012): 970-973. |
| Dawkins, Lynne, et al., “Acute electronic cigarette use: nicotine delivery and subjective effects in regular users,” Psychopharmacology, 2013. |
| Dawkins, Lynne, John Turner, and Eadaoin Crowe. “Nicotine derived from the electronic cigarette improves time-based prospective memory in abstinent smokers.” Psychopharmacology 227.3 (2013): 377-384. |
| Definition of “aerosol”, Merriam-Webster Dictionary, [online], no date, retrieved from the Internet, [retrieved Jun. 8, 2017], <URL: https://www.merriam-webster.com/dictionary/aerosol>. |
| Dezelic, M., et al., “Determination of structure of some salts of nicotine, pyridine and N-methylpyrrolidine on the basis of their infra-red spectra,” Spectrochimica Acta, vol. 23A, 1967. |
| Dixon, M., “On the Transfer of Nicotine from Tobacco to the Smoker. A Brief Review of Ammonia and “pH” Factors,” Contributions to Tobacco Research, vol. 19, No. 2, Jul. 2000. |
| Dong, J.Z., et al., “A Simple Technique for Determining the pH of Whole Cigarette Smoke,” Contributions to Tobacco Research, vol. 19, No. 1, Apr. 2000. |
| Drummond, M. Bradley, et al., “Electronic cigarettes. Potential harms and benefits.” Annals of the American Thoracic Society 11.2 (2014): 236-242. |
| Effros, R., et al., “The in Vivo pH of the Extravascular Space of the Lung,” The Journal of Clinical Investigation, vol. 48, 1969. |
| Eissenberg, Thomas. “Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration.” Tobacco control 19.1 (2010): 87-88. |
| Etter, Jean-François, et al., “Analysis of refill liquids for electronic cigarettes.” Addiction 108.9 (2013): 1671-1679. |
| Etter, Jean-François. “Levels of saliva cotinine in electronic cigarette users.” Addiction 109.5 (2014): 825-829. |
| Farsalinos, Konstantinos E., et al. “Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers.” International journal of environmental research and public health 11.4 (2014): 4356-4373. |
| Farsalinos, Konstantinos E., et al. “Evaluating nicotine levels selection and patterns of electronic cigarette use in a group of “vapers” who had achieved complete substitution of smoking.” Substance abuse: research and treatment 7 (2013): SART-S12756. |
| Farsalinos, Konstantinos E., et al. “Impact of flavour variability on electronic cigarette use experience: an internet survey.” International journal of environmental research and public health 10.12 (2013): 7272-7282. |
| Farsalinos, Konstantinos E., et al. “Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices.” Scientific reports 4 (2014): 4133. |
| Farsalinos, Konstantinos E., et al., “Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review.” Therapeutic advances in drug safety 5.2 (2014): 67-86. |
| Fournier, J., “Thermal Pathways for the Transfer of Amines, Including Nicotine, to the Gas Phase and Aerosols,” Heterocycles, vol. 55, No. 1, 2001. |
| Gonda, I., et al. “Smoking cessation approach via deep lung delivery of ‘clean’ nicotine.” RDD Europe (2009): 57-61. |
| Goniewicz, Maciej L., et al., “Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications.” Addiction 109.3 (2014): 500-507. |
| Grotenhermen, et al., Developing science-based per se limits for driving under the influence of cannabis (DUIC): findings and recommendations by an expert panel; retreived Feb. 9, 2017 from (http://www.canorml.org/healthfacts/DUICreport.2005.pdf); Sep. 2005. |
| Harris, Mark. “Warning cigarettes may be about to become fashionable again.” Engineering & Technology 6.1 (2011): 38-31. |
| Heyder, J., “Alveolar deposition of inhaled particles in humans,” American Industrial Hygiene Association Journal, 43:11, 864-866, 2010. |
| Hurt, R., et al., “Prying Open the Door to the Tobacco Industry's Secrets About Nicotine,” The Journal of the American Medical Association, vol. 280, 1998. |
| Keithly, Lois., et al., “Industry research on the use and effects of levulinic acid: A case study in cigarette additives,” Nicotine & Tobacco Research vol. 7, No. 5, 761-771, 2005. |
| Kosmider, L., et al. “Electronic cigarette—a safe substitute for tobacco cigarette or a new threat?.” Przeglad lekarski 69.10 (2012): 1084-1089. [including English language translation thereof]. |
| Lauterbach, J.H, “Comparison of Mainstream Cigarette Smoke pH With Mainstream E-Cigarette Aerosol pH” Tob. Sci. Res. Conf., 2013, 67, abstr. 78. 2013. |
| Lauterbach, J.H., “A Critical Assessment of Recent Work on the Application of Gas/Particle Partitioning Theories to Cigarette Smoke,” Contributions to Tobacco Research, vol. 19, No. 2, Jul. 2000. |
| Lauterbach, J.H., “Comment on Gas/Particle Partitioning of Two Acid-Base Active Compounds in Mainstream Tobacco Smoke: Nicotine and Ammonia,” J. Agric. Food Chem., vol. 58, No. 16, 2010. |
| Lauterbach, J.H., “Free-base nicotine in tobacoo products. Part 1. Determination of free-base nicotine in the particulate phase of mainstream cigarette smoke and the relevance of these findings to product design parameters,” Regulatory Toxicology and Pharmacology, 2010. |
| Lauterback (2013) “GC-MS analysis of e-liquids taken from e-cigarettes and e-liquids (e-juice) before use in e-cigarettes” Presentation Slides CORESTA. |
| Lee, L.-Y., et al., “Airway irritation and cough evoked by inhaled cigarette smoke: Role of neuronal nicotinic acetylcholine receptors,” Pulmonary Pharmacology & Therapeutics, vol. 20, 2007. |
| Leffingwell, J., et al., “Tobacco Flavoring for Smoking Products,” R.J. Reynolds Tobacco Company, 1972. |
| Lim, Heung Bin, et al., “Inhallation of e-cigarette cartridge solution aggravates allergen-induced airway inflammation and hyper-responsiveness in mice.” Toxicological research 30.1 (2014): 13. |
| Lippiello, P., et al., “Enhancement of Nicotine Binding to Nicotinic Receptors by Nicotine Levulinate and Levulinic Acid,” 1989. |
| Lux, J.E., et al., “Subjective Responses to Inhaled and Intravenous Injected Nicotine,” American Society for Clinical Pharmacology and Therapeutics, 1988. |
| Lux, J.E., et al., :Generation of a submicrometre nicotine aerosol for inhalation, Med. & Biol. Eng. & Comput. 26, 232-234, 1988. |
| MacDougall, James., et al., “Selective Cardiovascular Effects of Stress and Cigarette Smoking,” Journal of Human Stress, 9:3. 13-21, 1983. |
| McQueen, Amy, et al., “Interviews with “vapers”: implications for future research with electronic cigarettes.” Nicotine & Tobacco Research 13.9 (2011): 860-867. |
| McRobbie, Hayden, et al. “Electronic cigarettes for smoking cessation and reduction.” Cochrane Database Syst. Rev 12 (2012). |
| Nicotine Salts. RJ Reynolds Records. Nov. 9, 1990. https://www.industrydocumentslibrary.ucsf.edu/tobacoo/docs/ytyg0100. |
| Oldendorf, W., et al., “Blood-brain barrier penetration abolished by N-methyl quaternization of nicotine,” Proc. Natl. Acad. Sci, vol. 90, pp. 307-311, 1993. |
| Oldendorf, W., et al., “pH Dependence of Blood-Brain Barrier Permeability to Lactate and Nicotine,” Stroke, vol. 10, No. 5, 1979. |
| Omole, Olufemi Babatunde, et al., “Review of alternative practices to cigarette smoking and nicotine replacement therapy: how safe are they?.” South African Family Practice 53.2 (2011): 154-160. |
| Pachke, T., et al., “Effects of Ingredients on Cigarette Smoke Composition and Biological Activity: A Literature Overview,” Contributions to Tobacco Research, vol. 20, No. 2, Aug. 2002. |
| Pankow, et al., “Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base form Through the Action of Gaseous Ammonia,” Eniron. Sci. Technol. 31 (8), 1997. |
| Pankow, James F. “A consideration of the role of gas/particle partitioning in the deposition of nicotine and other tobacco smoke compounds in the respiratory tract.” Chemical research in toxicology 14.11 (2001): 1465-1481. |
| Perfetti, T., “Investigation of Nicotine Transfer to Mainstream Smoke I. Synthesis of Nicotine Salts,” 1978. |
| Perfetti, Transfer of Nicotine salts to mainstream smoke (2000) https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=rzwp0187. |
| Polosa, Riccardo, et al. “A fresh look at tobacco harm reduction: the case for the electronic cigarette.” Harm reduction journal 10.1 (2013): 19. |
| Polosa, Riccardo, et al. “Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study.” BMC public health 11.1 (2011): 786. |
| Polosa, Riccardo, et al. “Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal.” International journal of environmental research and public health 11.5 (2014): 4965-4977. |
| Polosa, Riccardo, et al. “Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study.” Internal and emergency medicine 9.5 (2014): 537-546. |
| Prignot, J., “Electronic Nicotine Delivery Systems (Electronic Cigarettes, Cigars, Pipes),” Louvain Medical, V. 132, No. 10, Dec. 2013. [including English language translation thereof]. |
| U.S. Appl. No. 61/826,318, filed May 22, 2013. |
| U.S. Appl. No. 61/856,286, filed Jul. 19, 2013. |
| U.S. Appl. No. 61/856,374, filed Jul. 19, 2013. |
| U.S. Appl. No. 61/891,626, filed Oct. 16, 2013. |
| U.S. Appl. No. 61/969,650, filed Mar. 24, 2014. |
| U.S. Appl. No. 61/971,340, filed Mar. 27, 2014. |
| Riggs, et al., “The Thermal Stability of Nicotine Salts,” R.J. Reynolds Tobacco Company, 2000. |
| Robertson, C., et al., “In their own words: an epoch of deceit and deception,” Chapter 5 (find out from which book). |
| Rose, J., “Nicotine and nonnicotine factors in cigarette addiction,” Psychopharmacology, 184:274-285, 2006. |
| Rose, J., “Pulmonary Delivery of Nicotine Pyruvate: Sensory and Pharmacokinetic Characteristics,” Expermimental and Clinical Psychopharmacology, vol. 18, No. 5, 2010. |
| Sahu, S.K., et al., “Particle Size Distribution of Mainstream and Exhaled Cigarette Smoke and Predictive Deposition in Human Repiratory Tract,” Aerosol and Air Quality Research, 13: 324-332, 2013. |
| Scenihr, “Addictiveness and Attractiveness of Tobacco Additives,” Scientific Committee on Emerging and Newly Identified Health Risks, Nov. 12, 2010. |
| Schripp, Tobias, et al. “Does e-cigarette consumption cause passive vaping?.” Indoor air 23.1 (2013): 25-31. |
| Schroeder, Megan J., et al., “Electronic cigarettes and nicotine clinical pharmacology.” Tobacco control 23.suppl 2 (2014): ii30-ii35. |
| Seeman, et al., “The form of nicotine in tobacco. Thermal transfer of nicotine and nicotine acid salts to nicotine in the gas phase,” J Aric Food Chem, 47(12), pp. 5133-5145. Dec. 1999. |
| Seeman, J., “Possible Role of Ammonia on the Deposition, Retention, and Absorption of Nicotine in Humans while Smoking,” Chemical Research in Toxicology, 20, 2007. |
| Seeman, J., “Using ‘Basic Principles’ to Understand Complex Science: Nicotine Smoke Chemistry and Literature Analogies,” Journal of Chemical Education, vol. 82, No. 10, 2005. |
| Seeman, J., et al., “On the Deposition of Volatiles and Semivolatiles from Cigarette Smoke Aerosols: Relative Rates of Transfer of Nicotine and Ammonia from Particles to the Gas Phase,” Chemical Research in Toxicology, 17, 2004. |
| Seeman, J., et al., “The possible role of ammonia toxicity on the exposure, deposition, retention, and the bioavailability of nicotine during smoking,” Food and Chemical Toxicology, 46, 2008. |
| Sensabaugh, A.J., et al., “A New Technique for Determining the pH of Whole Tobacco Smoke,” Tobacco Science. |
| Shahab, L., et al., “Novel Delivery Systems for Nicotine Replacement Therapy as an Aid to Smoking Cessation and for Harm Reduction: Rationale, and Evidence for Advantages over Existing Systems,” CNS Drugs, 27: 1007-1019, 2013. |
| Snowdon, Christopher. “Harm reduction and tobacco: a new opportunity or a step too far?.” Drugs and Alcohol Today 13.2 (2013): 86-91. |
| Stevenson, T., et al., “The Secret and Soul of Marlboro,” Public Health Then and Now, American Journal of Public Health, vol. 98, No. 7, 2008. |
| Teague, “Implications and Activites Arising from Correlation of Smoke pH with Nicotine Impact, Other Smoke Qualities and Cigarette Sales,” 1983. |
| Tomar, S., et al., “Review of the evidence that pH is a determinant of nicotine dosage from oral use of smokeless tobacco,” Tobacco Control, 6:219-225, 1997. |
| Torrie, B., “Nicotine inhaler gives instant ‘hit’,” 2 pages (2013), available at http://www.stuff.co.nz/national/health/8822875/Nicotine-inhaler-gives-instant-hit. |
| Travell, J., “The Influence of the Hydrogen Ion Concentration on the Absorption of Alkaloids from the Stomach,” The Journal of Pharmacology, Jan. 1940. |
| Trehy, Michael L., et al. “Analysis of electronic cigarette cartridges, refill solutions, and smoke for nicotine and nicotine related impurities.” Journal of Liquid Chromatography & Related Technologies 34.14 (2011): 1442-1458. |
| Uchiyama, Shigehisa, et al. “Determination of carbonyl compounds generated from the E-cigarette using coupled silica cartridges impregnated with hydroquinone and 2, 4-dinitrophenylhydrazine, followed by high-performance liquid chromatography.” Analytical sciences 29.12 (2013): 1219-1222. |
| Vansickel, Andrea R., et al. “A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects.” Cancer Epidemiology and Prevention Biomarkers 19.8 (2010): 1945-1953. |
| Vansickel, Andrea Rae, et al., “Electronic cigarettes: effective nicotine delivery after acute administration.” Nicotine & Tobacco Research 15.1 (2012): 267-270. |
| Wayne, G., et al., “Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents,” Tobacco Control, 15:189-198, 2006. |
| Weiss, G., “The Effect of pH on Nicotine-Induced Contracture and Ca45 Movements in Frog Sartorius Muscle,” The Journal of Pharmacology and Experimental Therapeutics, vol. 154, No. 3, 1966. |
| World Health Organization, “Health Effects of Interations Between Tobacco Use and Exposure to Other Agents,” Environmental Health Criteria 211, 83 pages (1999), available at http://www.inchem.org/documents/ehc/ehc/ehc211.htm. |
| Wynn III, William P., et al. “The pharmacist “toolbox” for smoking cessation: a review of methods, medicines, and novel means to help patients along the path of smoking reduction to smoking cessation.” Journal of pharmacy practice 25.6 (2012): 591-599. |
| Zenzen, Volker, et al. “Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 2: Smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior.” Regulatory Toxicology and Pharmacology 64.2 (2012): S11-S34. |
| Zhang, Yaping, et al., “In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns.” Nicotine & Tobacco Research 15.2 (2012): 501-508. |
| Clayton, et al., “Spectroscopic investigations into the acid-base properties of nicotine at different temperatures”, Analytical Methods, 2013, pp. 81-88, vol. 5. |
| Henningfield, et al., “Tobacco Control”, 1995, pp. 57-61, vol. 4. |
| Leffingwell, et al., “Basic chemical constituents of tobacco: production, chemistry and Technology”, Blackwell Science, 1999. |
| Maier, et al., “Polypropylene: the defintive user's guide and databook”, 1998. |
| Stepanov, et al., “Bringing attention to e-cigarette pH as an important element for research and regulation”, Tob. Control, May 14, 2014, vol. 24, No. 4. |
| Burn et al., “Action of Nicotine on the Heart”, Excretion of Piperazine Salts, British Medical Journal, Jan. 18, 1958, pp. 137-139. |
| Number | Date | Country | |
|---|---|---|---|
| 20160044967 A1 | Feb 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61912507 | Dec 2013 | US | |
| 61820128 | May 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14271071 | May 2014 | US |
| Child | 14925961 | US |
